Stockwinners Market Radar for January 02, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
RXRX | Hot Stocks20:03 EST Cathie Wood's ARK Investment bought 128K shares of Recursion Pharmaceuticals
|
RKLB | Hot Stocks20:03 EST Cathie Wood's ARK Investment bought 255K shares of Rocket Lab today
|
ROKU | Hot Stocks20:02 EST Cathie Wood's ARK Investment bought 190K shares of Roku
|
TENX | Hot Stocks19:50 EST Tenax Therapeutics trading halted, news pending
|
LXEH | Hot Stocks19:50 EST Lixiang Education Holding Co Ltd - ADR trading halted, news pending
|
PRSO | Hot Stocks19:50 EST MoSys trading halted, news pending
|
CEO | Hot Stocks19:02 EST Cnooc's Lufeng Oilfields Phase II project begins production - CNOOC Limited announces that Lufeng Oilfields Phase II Development Project has commenced production. The project is located in the eastern South China Sea, with an average water depth of approximately 136 meters. It consists of Lufeng 8-1 Oilfield, Lufeng 9-2 Oilfield and Lufeng 14-8 Oilfield. One new drilling platform is built, and 14 development wells are planned to be put into production, including 13 production wells and 1 water-injection well. The project is expected to achieve a peak production of approximately 22,600 barrels of crude oil per day in 2025.
|
META | Hot Stocks18:52 EST Meta Platforms exec sells $3.6M in common stock - In a regulatory filing, Meta Platforms disclosed that its Chief Product Officer Christopher Cox sold 10K shares of common stock on December 28th in a total transaction size of $3.6M.
|
GSAT | Hot Stocks18:25 EST Globalstar director buys $963.7K in common stock - In a regulatory filing, Globalstar disclosed that its director James Lynch bought 500K shares of common stock on December 29th in a total transaction size of $963.7K.
|
MHLD | Hot Stocks18:01 EST Maiden Holdings director Neuberger sells 277,000 common shares - In a regulatory filing, Maiden Holdings director Yehuda Neuberger disclosed the sale of 277,000 common shares of the company on December 31 at a price of $2.29 per share.
|
ID | Hot Stocks17:25 EST Parts iD announces delisting from NYSE American - PARTS iD "announced that it received notification from the New York Stock Exchange that the NYSE has initiated proceedings to delist the Class A common stock of PARTS iD, Inc. from NYSE American. The NYSE also indefinitely suspended trading of the Company's Class A common stock effective December 26, 2023. PARTS iD does not intend to appeal the NYSE's determination."
|
PDCO CHS | Hot Stocks17:23 EST Patterson Companies to replace Chico's in S&P 600 at open on 1/5 - Sycamore Partners is acquiring Chico's FAS in a transaction expected to be completed on or about that date pending final conditions.
|
PSTG PDCO | Hot Stocks17:22 EST Pure Storage to replace Patterson Companies in S&P 400 at open on 1/5
|
EGO | Hot Stocks17:11 EST Eldorado Gold names Paul Ferneyhough as new CFO - Eldorado Gold "announces the appointment of Paul Ferneyhough as Executive Vice President and Chief Financial Officer of the Company to be effective today, January 2, 2024. Mr. Ferneyhough will be succeeding Philip Yee, who will be retiring as of the same date. Paul Ferneyhough joined Eldorado Gold in May 2021 to oversee the development and execution of the Company's strategic growth strategy. Most recently, Paul was Executive Vice President, Chief Strategy & Commercial Officer of Eldorado, with accountabilities including Country Management (Canada, Greece and Turkiye), Investor Relations, Sales & Marketing, Business Improvement, and Supply Chain & Procurement. Paul joined the Company as Senior Vice President, Chief Growth and Integration Officer. In that role, Paul was Eldorado's lead negotiator for the Skouries Project Financing Facility that was successfully closed at very competitive rates in early 2023. Prior to joining Eldorado Gold, Paul spent nearly two decades with Repsol SA (and Talisman Energy), most recently as Executive Director leading Repsol's North American upstream oil and gas division."
|
ASTS | Hot Stocks17:01 EST AST SpaceMobile provides update on fundraising - AST SpaceMobile provided an interim update on fundraising progress. The company states it is "now seeking to close and fund the previously disclosed strategic investment in January 2024 with multiple parties, subject to completion of final documentation and approvals" and that it has "secured initial ground infrastructure orders from two customers for planned commercial service". Shares of AST SpaceMobile are up 6% afterhours at $5.15.
|
CENX | Hot Stocks17:01 EST Century Aluminum Treasurer PeterTrpkovski sells 14K shares of company stock - Century Aluminum Treasurer PeterTrpkovski disclosed the sale of 13,908 shares of company stock at $12.32 per share on December 28 for a total transaction amount of $171,347.
|
BLMN | Hot Stocks16:56 EST Bloomin' Brands up 3% at $28.25 after Starboard Value board appointments
|
GNRC | Hot Stocks16:52 EST Generac CEO Jagdfeld sells 5,000 common shares - In a regulatory filing, Generac Holdings CEO Aaron Jagdfeld disclosed the sale of 5,000 common shares of the company on January 2 at a price of $127.28 per share.
|
MDB | Hot Stocks16:50 EST MongoDB director sells $987K in common stock - In a regulatory filing, MongoDB disclosed that its director Dwight Merriman sold 2.4K shares of common stock on December 28th in a total transaction size of $987K.
|
GLYC TMO | Hot Stocks16:41 EST GlycoMimetics in manufacturing pact with Thermo Fisher for uproleselan - On January 2, GlycoMimetics (GLYC) entered into a project agreement with Patheon Manufacturing Services part of Thermo Fisher Scientific (TMO), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration. The Project Agreement is subject to the additional terms of a Master Services Agreement previously entered into by the Company and Patheon that governs the general terms under which Patheon will provide non-exclusive manufacturing and commercial services to the Company from time to time...Pursuant to the Project Agreement, Patheon will manufacture commercial supplies of injectable uproleselan from active pharmaceutical ingredient supplied by the Company. Patheon will be responsible for supplying the other required raw materials and packaging components and will also provide supportive manufacturing services such as quality control testing for raw materials, packaging components and finished product. Under the Project Agreement, the Company has provided Patheon with its forecast of required annual volumes through 2027. The Project Agreement has an initial term through December 31, 2026 and will automatically renew for additional three-year periods unless earlier terminated. After the initial term, either party may terminate the Project Agreement by giving 18 months' written notice for any business reason. Either party may terminate the Project Agreement within a given time period upon any material breach that is left uncured by the other party. Upon completion, expiration and/or termination of the Project Agreement, the Company will pay Patheon for all service rendered, all costs and expenses incurred and any termination fees. This information was provided in a company 8K filing. Reference Link
|
SABS | Hot Stocks16:33 EST SAB Biotherapeutics announces 1-for-10 reverse stock split - SAB Biotherapeutics announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on January 5. SAB's common stock will continue to be traded on the Nasdaq capital market under the symbol (SABS) and will begin trading on a reverse stock split-adjusted basis at the opening of the market on Friday, January 5. The new CUSIP number for the split-adjusted common stock will be 78397T 202. SAB's publicly traded warrants will continue to trade on Nasdaq under the symbol "SABSW" and the CUSIP number for the warrants will remain unchanged At the company's special meeting of stockholders on January 2, the stockholders approved a proposal to amend the company's Certificate of Incorporation to affect a reverse split of the company's outstanding common stock at a ratio in the range of 2-for-3 to 1-for-10, with such final ratio to be determined at the discretion of the board of directors (the "Board"). The specific 1-for-10 ratio was subsequently determined by the board following the conclusion of the special stockholders meeting. The reverse stock split is primarily intended to increase SAB's per share trading price to bring SAB into compliance with Nasdaq's listing requirement regarding minimum share price and maintain SAB's listing on Nasdaq.
|
HLF | Hot Stocks16:32 EST Herbalife names Stephan Gratziani president - Herbalife announced the appointment of Stephan Paulo Gratziani to President, effective January 2, 2024, as part of the Company's management succession planning process. Mr. Gratziani will continue to report directly to Chairman and Chief Executive Officer, Michael Johnson. "Stephan hit the ground running and has demonstrated his extensive knowledge of the business and strategic strength in his role as Chief Strategy Officer," said Michael Johnson, Chairman and CEO. "Stephan has an innate ability to lead, drive change and inspire others. We believe his innovative mindset and vast experience as a former leading independent distributor position him well to lead our global sales initiatives and guide Herbalife towards our next chapter of growth." In his new role, Gratziani will partner with the Company's three Regional Presidents and the regional teams to drive transformative change and implement strategic initiatives that are central to the Company's top-line sales growth. The three Regional Presidents will report directly to Gratziani.
|
BLMN DRI | Hot Stocks16:30 EST Dave George and Jon Sagal of Starboard Value appointed to Bloomin's Board - Bloomin' Brands (BLMN) announced the appointment of Dave George, former Chief Operating Officer of Darden Restaurants (DRI), and Jon Sagal, Partner at Starboard Value together with certain of its affiliates, to the Company's Board of Directors, effective immediately. These appointments have been made in connection with a cooperation agreement entered into between the Company and Starboard, which owns approximately 9.7% of the Company's outstanding common stock, and reflect the Company's ongoing commitment to constructive shareholder engagement. Jeffrey Smith, Chief Executive Officer and Chief Investment Officer of Starboard, commented, "Throughout the course of our engagement with Bloomin' Brands, we have appreciated the collaborative and open dialogue we have had with members of the Board and management team. Bloomin' Brands has a great portfolio of brands along with compelling growth levers and opportunities for value creation." In addition, the Company today announced the formation of an Operating Committee of the Board. This Committee will work with management to identify and recommend opportunities for further improvement related to various corporate and operational matters. Dave George will serve as the Chair of the Committee, and Jon Sagal and current directors Mike Mohan and John Mahoney have been appointed as members. Under the cooperation agreement, Starboard has agreed to customary standstill, voting and other provisions. The full agreement between Bloomin' Brands and Starboard will be filed on a Form 8-K with the U.S. Securities and Exchange Commission .
|
MOD | Hot Stocks16:20 EST Modine Manufacturing purchases IP, specific assets of TMG Core - Modine announced that it had purchased the intellectual property and other specific assets of TMG Core, a specialist in single- and two-phase liquid immersion cooling technology for data centers with high-density computing requirements. "Modine's investment in liquid immersion cooling technology advances our strategy to expand our global data center product offering and capture market opportunities that help us achieve our long-term growth targets," said Neil Brinker, President and CEO of Modine. "This investment strengthens Modine's position in the rapidly growing data center market, providing our customers with advanced solutions to support high-density, accelerated computing applications, such as generative artificial intelligence, 5G and machine learning."
|
COST | Hot Stocks16:19 EST Costco exec sells $928K in common stock - In a regulatory filing, Costco disclosed that its Principal Accounting Officer Daniel Hines sold 1.4K shares of common stock on December 28th in a total transaction size of $928K.
|
SJM THS | Hot Stocks16:17 EST J.M. Smucker completes sale of fermented condiment brands to TreeHouse - The J.M. Smucker Co. (SJM) announced the closing of the transaction to sell its Bick's pickles, Habitant pickled beets, Woodman's horseradish and McLarens pickled onions brands to TreeHouse Foods (THS). The all-cash transaction is valued at approximately $20M, subject to a working capital adjustment. The company previously announced the signing of a definitive agreement for the transaction on October 17, 2023. The company expects the impact of the divestiture to be immaterial to its adjusted earnings per share on a full-year basis. The company will provide additional information about the transaction's impact on its fiscal year 2024 outlook during the next quarterly earnings call.
|
PSTG | Hot Stocks16:16 EST Pure Storage CFO sells 26,257 common shares - In a regulatory filing, Pure Storage CFO P. Kevan Krysler disclosed the sale of 26,257 class A common shares of the company on December 28 at a price of $35.89 per share.
|
PGTI | Hot Stocks16:15 EST PGT Innovations up 4% at $41.75 following Miter Brands takeover proposal - Shares of PGT Innovations are up about 4% or $1.51 afterhours at $41.75 as shares resume trading after the company disclosed an unsolicited takeover proposal from Miter Brands to acquire all outstanding shares of PGT Innovations' common stock for $41.50 per share in cash.
|
WINT | Hot Stocks16:09 EST Windtree Therapeutics announces reduction in arrythmias in istaroxime study - Windtree Therapeutics announced new preclinical data on the company's lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury. Istaroxime and CVie-216 are each designed to act on pumps in the cardiac cells that are important in calcium handling. Istaroxime is a dual mechanism of action compound that has been shown to inhibit the sodium potassium ATPase and activates SERCA2a. CVie-216 is designed to selectively activate SERCA2a. Nearly 300 patients with acute decompensated heart failure were treated with istaroxime in three Phase 2 studies, including a study that evaluated patients with early cardiogenic shock. In these studies, istaroxime has not been associated with an increase in clinically significant arrythmias, raising the potential for a new therapy with substantial advantages over current rescue drug therapies used to treat acute heart failure and cardiogenic shock. Windtree is continuing to obtain data to evaluate the potential benefits of SERCA2a activation on arrythmia risk in all ongoing clinical trials. To further explore this potential benefit associated with SERCA2a activation, Windtree conducted a study of restricted and restored coronary blood flow induced injury in the hearts of rats with diabetes that were infused with either istaroxime, pure SERCA2a activator CVie-216 or placebo. The rat model generated a reproducible incidence of ventricular arrythmias. This study demonstrated a reduction in arrythmias in the istaroxime and CVie-216 pretreated groups compared to the control group. The company plans to publish the results and is in the process of pursuing additional intellectual property protection based on these findings.
|
PGTI | Hot Stocks16:07 EST PGT, Inc. trading resumes
|
SENS | Hot Stocks16:07 EST Senseonics sees Q4 revenue of about $8.0M, consensus $7.5M - "Our progress in 2023 represents continued execution across our strategic initiatives to advance both the adoption of Eversense and our product development programs for the world's first and only long-term CGM. Significant new lead generation from advertising campaign activities in the fourth quarter by our global commercial partner Ascensia Diabetes Care demonstrated strong patient response to the Eversense message. Now Ascensia is working to accelerate and improve the conversion of those leads by enhancing its CGM-dedicated commercial infrastructure," said Tim Goodnow, CEO. "As we look ahead to 2024, we expect Ascensia to upgrade lead conversions so they can work down their current inventory received in the fourth quarter to support demand through the upcoming product innovation cycle. We are targeting FDA submission of a 365-day, once a week calibration product and expect this product to drive a positive inflection in healthcare provider adoption and patient demand. We believe that leveraging this next-generation sensor platform, which is also the basis for our planned Gemini and Freedom systems, will provide development advantages in future product development cycles and support the long-term growth and adoption of Eversense."
|
RGLS | Hot Stocks16:06 EST Regulus completes enrollment in third cohort of Phase 1b trial of RGLS8429 - Regulus Therapeutics announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of our third and final randomized placebo-controlled cohort in the Phase 1b MAD study is an exciting step for Regulus, and we are happy to reach this stage of development for RGLS8429," said Jay Hagan, CEO of Regulus. "Our team is motivated and gearing up for 2024 when we expect topline data from our second cohort in Q1 2024, topline data from our third cohort in mid-2024, and the initiation of the fourth cohort, an open label fixed dose, of RGLS8429."
|
FND | Hot Stocks16:06 EST Floor & Decor announces grand opening of Mansfield, Texas store - Floor & Decor announced the grand opening of its eleventh warehouse location in Dallas/Ft Worth, with the addition of its newest location in Mansfield at 1925 FM 157. The warehouse store and design center opened on December 30, 2023, with a team of about 50 full-time and part-time associates led by Elijah Bogdan, the store Chief Executive Merchant. "We're thrilled to announce our newest store location in Mansfield," said Bogdan. "For more than two decades, Floor & Decor has had the opportunity to serve professionals and homeowners throughout the nation, and we are excited to expand our footprint in the Dallas/Ft Worth market with this new location. We look forward to becoming part of the community and welcoming our newest neighbors into our store and making their renovation journeys easier, inspired and more affordable."
|
OZK | Hot Stocks16:05 EST Bank OZK boosts dividend 2.7% or 1c to 38c per share - Bank OZK nnounced its Board of Directors declared a quarterly cash dividend on the Bank's common stock of 38c per share, up $0.01, or 2.70% from the prior quarter. The common stock dividend is payable on January 23, to shareholders of record as of January 16 . Bank OZK has increased its quarterly cash dividend on its common stock in each of the last fifty-four quarters.
|
FELE | Hot Stocks16:03 EST Franklin Electric to acquire LCA Pump, terms undisclosed - Franklin Electric announced that on its wholly owned subsidiary Headwater Companies acquired substantially all of the assets of LCA Pump, a Missouri limited liability company, which operates Water Works Pump. Water Works is a professional groundwater distributor located in Springfield, Missouri and will operate as a branch of Headwater Wholesale, a subsidiary of Headwater Companies.
|
TIO | Hot Stocks16:02 EST U.S. charges ex- co-CEO of Tingo Group Odogwu Banye Mmobuosi with fraud - Damian Williams, the United States Attorney for the Southern District of New York, and James Smith, the Assistant Director in Charge of the New York Field Office of the Federal Bureau of Investigation, FBI , announced the unsealing of an Indictment charging ODOGWU BANYE MMOBUOSI, a/k/a "Dozy Mmobuosi," with securities fraud, making false filings with the Securities and Exchange Commission or SEC, and conspiracy charges. MMOBUOSI is still at large. U.S. Attorney Damian Williams said: "Dozy Mmobuosi allegedly orchestrated a massive scheme to inflate Tingo Group's (TIO) financial statements and make it appear as though the cellular and agriculture companies he founded were profitable and cash rich companies when, in fact, they were not. With this Indictment, Mmobuosi's alleged deceitful scheme comes to an end." According to the allegations contained in the Indictment unsealed in Manhattan federal court and court filings: From at least in or about 2019 through in or about 2023, ODOGWU BANYE MMOBUOSI orchestrated a scheme to enrich himself by falsely representing that Nigerian companies he founded, Tingo Mobile and Tingo Foods, were operational, profitable businesses generating hundreds of millions of dollars in revenue respectively. MMOBUOSI then sold Tingo Mobile and Tingo Foods to companies listed in the United States, including Tingo Group listed on Nasdaq as and Agri-Fintech Holdings, traded in the Over-the-Counter Markets under symbol TMNA . As a result, MMOBUOSI caused Tingo Group and Agri-Fintech to issue financial statements that falsely portrayed Tingo Mobile and Tingo Foods to be cash-rich, revenue-generating companies when, in fact, they were not. MMOBUOSI then looted Tingo Group and Agri-Fintech by misappropriating cash from those companies and engaged in well-timed sales of their shares at inflated prices, generating millions of dollars of profits from his scheme. Reference Link
|
EGIO | Hot Stocks16:01 EST Edgio names Todd Hinders as new CEO - Edgio announced that Todd Hinders has been promoted to the position of CEO, effective immediately. Mr. Hinders has also joined the company's board of directors. Hinders takes over from Bob Lyons, who has resigned from his role as President and CEO and as a member of the board of directors.
|
PGTI DOOR | Hot Stocks15:54 EST PGT Innovations receives unsolicited takeover proposal from Miter Brands - PGT Innovations (PGTI) said it has received an unsolicited proposal from Miter Brands to acquire all outstanding shares of PGT Innovations' common stock for $41.50 per share in cash. As announced on December 18, 2023, PGT Innovations entered into a definitive agreement to be acquired by Masonite International Corp. (DOOR) for $41.00 per share in cash and Masonite stock, representing a premium of approximately 56.5% over the closing price per share of PGTI common stock of $26.20 on October 9, 2023. Consistent with the terms of the Masonite merger agreement, PGT Innovations' Board of Directors, in consultation with its independent financial and legal advisors, will carefully review Miter Brands' proposal to determine if it is reasonably likely to lead to a superior proposal. PGT Innovations will have no further comment on Miter's proposal until the Board of Directors has completed its review. PGT Innovations' shareholders are advised to take no action at this time. Evercore is acting as exclusive financial advisor to PGT Innovations, and Davis Polk & Wardwell LLP is acting as legal counsel to PGT Innovations.
|
PGTI | Hot Stocks15:23 EST PGT, Inc. trading halted, news pending
|
NYT | Hot Stocks14:45 EST Farallon Equity discloses 5.8% passive stake in New York Times - Farallon Equity Partners disclosed a 5.8% passive stake in New York Times, which represents over 9.47M shares.
|
VNRX HSKA | Hot Stocks13:32 EST VolitionRx announces receipt of $13M in milestone payments from Heska - In a regulatory filing, VolitionRx (VNRX) said that on December 29, 2023, the company received $13M in milestone payments from Heska Corporation (HSKA), pursuant to the License and Supply Agreement entered into on March 28, 2022, between Belgian Volition SRL, a wholly-owned subsidiary of the company, and Heska. The milestone payments arose from the successful assay transfer of the Nu.Q Vet Cancer Test onto Heska's Element i+ Immunodiagnostic Analyzer, a point of care platform for use by veterinarians and designated the "Heska Nu.Q Vet Canine Cancer Screen and Monitor" test.
|
MCAF | Hot Stocks13:08 EST Mountain Crest Acquisition Corp IV trading resumes
|
MCAF | Hot Stocks13:03 EST Mountain Crest Acquisition Corp IV trading halted, volatility trading pause
|
GCTK | Hot Stocks12:35 EST GlucoTrack reports early accuracy data for implantable GBGM - GlucoTrack provided an update on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor. The company announced the "successful" completion of their first preclinical study of the implantable CBGM. The study's objective was to assess implant technique and device safety. In addition, a small sample size of sensors was used to determine device functionality. Although not intended to be an accuracy study, the sensor demonstrates a Mean Absolute Relative Difference of 8.1% at Day 30 and 4.5% at Day 60. The study was completed with no significant adverse effects. "We are extremely pleased with these initial results demonstrating that the sensor is both safe and capable of a high level of accuracy" states Paul Goode, PhD, CEO of GlucoTrack. "Because this study was performed using initial prototype devices, we expect to see similar results with improved prototypes that are manufactured using refined production techniques. So, we are very confident as we continue to advance our development program and as we share more information about our novel approach." The company also announced a second milestone: the commencement of long-term preclinical testing on the implantable CBGM. The objective of this study is to assess sensor accuracy and longevity with a refined prototype and larger sample size. The company is preparing for first-in-human studies which are expected to start later this year.
|
TSEM | Hot Stocks12:23 EST Tower Semiconductor reports no damage to buildings following Japan earthquake - Tower Semiconductor provides an update following the recent earthquake in Ishikawa Prefecture in Japan, the neighboring Prefecture to where its two Japanese manufacturing facilities are located. The company said, "The Company expresses relief and gratitude as it reports that all employees are safe. Prioritizing the well-being of its team, Tower remains committed to ensuring their safety during the recovery phase. There was no impact or damage to the buildings and only minor damage to the facilities which had no impact on operations. The dedicated staff and response teams have worked to ensure operational safety and stability. Tools requalification is underway, combined with efforts to efficiently repair any damage to fab tools and in-line materials, while utilizing all available resources to minimize any potential disruptions to manufacturing and customer service."
|
IBKR | Hot Stocks12:14 EST Interactive Brokers reports December DARTs up 13% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for December. Brokerage highlights for the month included: 1.972 million Daily Average Revenue Trades, 13% higher than prior year and 4% higher than prior month. Ending client equity of $426B, 39% higher than prior year and 5% higher than prior month. Ending client margin loan balances of $44.4 billion, 14% higher than prior year and 5% higher than prior month . Ending client credit balances of $104.5B, including $3.7B in insured bank deposit sweeps, 10% higher than prior year and 3% higher than prior month. 2.56 million client accounts, 23% higher than prior year and 2% higher than prior month. 172 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.17 including exchange, clearing and regulatory fees.
|
SNX | Hot Stocks12:05 EST Shyft Global Services acquires Cokeva, terms not disclosed - Shyft Global Services, a division of TD SYNNEX, announced that it has acquired Cokeva. The addition of Cokeva expands Shyft's depot repair service capabilities and unlocks additional opportunities for Shyft customers with Cokeva's 220,000 sq. ft. operation in Roseville, California. This facility holds a certification for ISO 9001:2015 Quality Management Systems and operates a cleanroom to ISO 5/Class 100 standards. The addition of the Roseville facility bolsters Shyft's global footprint, which includes certified facilities in Groveport, Ohio; Warsaw, Poland; Tiel, Netherlands; and Tampines, Singapore. Founded in 1989, Cokeva has become an industry leader in the high-complexity, high-value and mission-critical IT repair, test and refurbishment market through its commitment to individualized customer service, impeccable quality, sustainability, competitive pricing and continuous improvements. The company has a long history of exceeding customer satisfaction benchmarks and being a highly rated supply chain partner for original equipment manufacturers.
|
ACON | Hot Stocks12:02 EST Aclarion announces 1-for-16 reverse stock split - Aclarion announced that effective before market open on Thursday January 4, 2024, it will complete a 1-for-16 reverse stock split of its common stock. On March 24, 2023, the Company's stockholders approved an amendment to the Company's Certificate of Incorporation to affect a reverse stock split with the exact ratio to be set by its Board of Directors. The Board resolved to set the reverse stock split at the ratio of 1-for-16. The Company filed an amendment to its Certificate of Incorporation with the Secretary of State in Delaware effective January 3, 2024, at 5:00 p.m. Eastern Time. As a result, every sixteen issued shares of common stock will automatically be combined into one share of common stock. The Company believes that affecting the reverse stock split will assist in its efforts to meet the Nasdaq continued listing standards and to continue to have its common stock remain listed and traded on Nasdaq. In particular, the Company expects the reverse stock split to increase the per share price and bid price of its common stock above the $1.00 required by Nasdaq's Minimum Bid Price Rule. Shares of the Company's common stock will be assigned a new CUSIP number and are expected to begin trading on a split-adjusted basis on Thursday, January 4, 2024. The reverse stock split will not change the authorized number of shares of the Company's common stock. No fractional shares will be issued and any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. Therefore, stockholders with less than 16 shares will receive one share of stock.
|
OPFI | Hot Stocks12:00 EST OppFi falls -8.4% - OppFi is down -8.4%, or -43c to $4.69.
|
SNDA | Hot Stocks12:00 EST Sonida Senior Living falls -8.6% - Sonida Senior Living is down -8.6%, or -83c to $8.83.
|
AMPX | Hot Stocks12:00 EST Amprius Technologies falls -11.0% - Amprius Technologies is down -11.0%, or -58c to $4.71.
|
HIMS | Hot Stocks12:00 EST Hims & Hers rises 8.7% - Hims & Hers is up 8.7%, or 77c to $9.67.
|
UP | Hot Stocks12:00 EST Wheels Up rises 10.3% - Wheels Up is up 10.3%, or 35c to $3.78.
|
ZIM | Hot Stocks12:00 EST ZIM Integrated rises 11.4% - ZIM Integrated is up 11.4%, or $1.12 to $10.99.
|
PMD | Hot Stocks11:29 EST Psychemedics relocates headquarters to Dallas, Texas - Psychemedics Corporation announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
|
NUBI | Hot Stocks11:22 EST Nubia Brand International Corp trading resumes
|
NUBI | Hot Stocks11:12 EST Nubia Brand International Corp trading halted, volatility trading pause
|
VSTE | Hot Stocks11:09 EST Vistra Energy Corp. trading resumes
|
NCAC | Hot Stocks11:06 EST Newcourt Acquisition Corp trading resumes
|
VSTE | Hot Stocks11:04 EST Vistra Energy Corp. trading halted, volatility trading pause
|
NCAC | Hot Stocks11:01 EST Newcourt Acquisition Corp trading halted, volatility trading pause
|
GH | Hot Stocks11:01 EST Guardant Health names Terilyn Juarez Monroe as chief people officer - Guardant Health announced the addition of Terilyn Juarez Monroe as the company's chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, is transitioning to an advisory role with the company. Prior to joining Guardant, Monroe held numerous human resources leadership roles, including as chief people officer at Bonterra, Varian, and Acxiom.
|
DOGZ | Hot Stocks10:02 EST Dogness Internationa trading resumes
|
POL | Hot Stocks10:01 EST Polished.com trading resumes
|
BITO | Hot Stocks10:00 EST ProShares Bitcoin Strategy ETF rises 9.6% - ProShares Bitcoin Strategy ETF is up 9.6%, or $1.96 to $22.45.
|
ZIM | Hot Stocks10:00 EST ZIM Integrated rises 10.2% - ZIM Integrated is up 10.2%, or $1.00 to $10.87.
|
SOS | Hot Stocks10:00 EST SOS Limited rises 10.2% - SOS Limited is up 10.2%, or 47c to $5.07.
|
BITI | Hot Stocks10:00 EST Biotie Therapies falls -9.6% - Biotie Therapies is down -9.6%, or -$1.26 to $11.89.
|
AKA | Hot Stocks10:00 EST a.k.a. Brands falls -11.9% - a.k.a. Brands is down -11.9%, or -96c to $7.09.
|
PNST | Hot Stocks10:00 EST Pinstripes falls -16.3% - Pinstripes is down -16.3%, or -$1.78 to $9.12.
|
POL | Hot Stocks09:56 EST Polished.com trading halted, volatility trading pause
|
LBPH | Hot Stocks09:54 EST Longboard rallies 188% to $17.37 after data, Cantor boosts target to $55
|
RCAC | Hot Stocks09:53 EST Revelstone Capital Acquisition Corp trading resumes
|
DOGZ | Hot Stocks09:51 EST Dogness Internationa trading halted, volatility trading pause
|
RCAC | Hot Stocks09:48 EST Revelstone Capital Acquisition Corp trading halted, volatility trading pause
|
LDI | Hot Stocks09:47 EST LoanDepot falls -8.1% - LoanDepot is down -8.1%, or -28c to $3.23.
|
INSP | Hot Stocks09:47 EST Inspire Medical falls -9.0% - Inspire Medical is down -9.0%, or -$18.30 to $185.13.
|
BITI | Hot Stocks09:47 EST Biotie Therapies falls -9.5% - Biotie Therapies is down -9.5%, or -$1.25 to $11.89.
|
BITO | Hot Stocks09:47 EST ProShares Bitcoin Strategy ETF rises 9.5% - ProShares Bitcoin Strategy ETF is up 9.5%, or $1.95 to $22.44.
|
BTCM | Hot Stocks09:47 EST BIT Mining rises 12.1% - BIT Mining is up 12.1%, or 61c to $5.65.
|
SOS | Hot Stocks09:47 EST SOS Limited rises 13.0% - SOS Limited is up 13.0%, or 60c to $5.20.
|
KSCP | Hot Stocks09:40 EST Knightscope announces order of 13 K1 Blue Light E-Phones for GSU - Knightscope announces its first order of 13 K1 Blue Light E-Phones for Georgia State University by Knightscope Authorized Partner Transportation Solutions & Lighting, Safety and Security Division, National Safety System. As announced in July 2023, this is the first of what is ultimately expected to be more than 50 emergency communication devices to be installed at the downtown Atlanta campus by TS&L.
|
ABL | Hot Stocks09:35 EST Abacus Life Inc trading resumes
|
ABL | Hot Stocks09:30 EST Abacus Life Inc trading halted, volatility trading pause
|
BETS | Hot Stocks09:27 EST Bit Brother Limited signs consulting agreement for new investment opportunities - Bit Brother Limited announced the execution of a consulting agreement with Cruxforce aiming to find a mining farm with sufficient power supply for the third site. In December 2023, Bitcoin once again sparked a surge, surpassing $45K per coin. Seizing this chance to actively pursue investment expansion opportunities, Bit Brother has entered into a consulting agreement with Cruxforce, aiming to find a mining farm with ample power supply for site 3. Cruxforce will search for mining sites with a maximum power supply capacity of 40MW to meet Bit Brother's growing demands for mining operations.
|
MULN | Hot Stocks09:26 EST Mullen Automotive delivers 50 Class 1 EV cargo vans to Randy Marion - Mullen Automotive announces 50 additional Class 1 EV cargo vans have been delivered and invoiced for $1,681,750 to Randy Marion Automotive Group. To date, the Company has delivered 100 Mullen ONE, Class 1 cargo vans for a total invoiced amount of $3,363,500. Mullen is on target to deliver a total of 285 Class 1 vehicles by Jan. 8, 2024.
|
TRNO | Hot Stocks09:19 EST Terreno Realty sells industrial property in California for $15.9M - Terreno Realty sold an industrial property located in Compton, California for a sale price of approximately $15.9M. The property consists of a 58,000 square foot industrial distribution building on three acres which is 100% leased to one tenant. The property was purchased by Terreno Realty Corporation on July 21, 2017 for approximately $9.4M. The unleveraged internal rate of return generated by the investment was 13%.
|
CIFR | Hot Stocks09:16 EST Cipher Mining mines 465 bitcoin in December - Cipher produced ~465 BTC in December, representing a ~7.4% increase in production versus the previous month amidst average monthly network hash rate increasing ~6.3% in December relative to the previous month. As part of its regular treasury management process, Cipher sold ~228 BTC in December, ending the month with a balance of ~796 BTC. "Cipher delivered another month of increased production in December, despite continued growth in network hash rate," said Tyler Page, CEO of Cipher. "Elevated transaction fees on the Bitcoin network, optimal mining conditions in Texas, and a relentless focus from our operations team produced fantastic results. We also entered into transactions to acquire new cutting-edge mining rigs for our increasingly ambitious growth plans. We finished the year with ample total liquidity of approximately $120 million in bitcoin2 and dollars, with no debt overhang."
|
AIMD | Hot Stocks09:09 EST Ainos regains compliance with Nasdaq minimum bid price rule - Ainos announced that on December 29, 2023, the Company received a written notice from The Nasdaq Stock Market. The notice informed Ainos that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. On January 5, 2023, Ainos was notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. To regain compliance with the Rule, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. This requirement was met on December 28, 2023.
|
BLNK... | Hot Stocks09:09 EST Blink Charging reflects on growth, achievements in 2023 - Blink Charging (BLNK) reflects upon a year that saw growth, new opportunities, and achievements for the Company. The company said, "Blink began 2023 on a high note by unveiling an exclusive agreement with Mitsubishi (MSBHF) to implement EV charging infrastructure across Mitsubishi's nationwide dealer network. As a result, Blink chargers, the Blink Network, and Blink's turnkey services were made available to all 323 Mitsubishi dealerships nationwide. This impactful agreement represented just one of the Company's many collaborations throughout 2023, augmented by a successful $100 million capital raise in January that kicked off Blink's impressive year... March saw one of Blink's most impactful announcements to date. The Company proudly announced its contract with the United States Postal Service to provide up to 41,500 EV charging stations and network services for USPS's electric future... In May, Blink announced the Company's leadership would be entrusted to EV industry veteran and then Blink President, Brendan Jones... Continuing the Company's mission to support EV drivers at home and on the road, Blink signed an agreement with AAA in July to offer electric vehicle products to affiliated roadside service providers nationwide... Blink has proven its readiness to support major global companies' charge into the EV future - as the Company did in August, when it signed an agreement with global quick service franchisee, Arcos Dorados (ARCO), to provide EV charging to five McDonald's locations throughout Puerto Rico... Finally, the Company's announcement of its record-breaking revenue in third quarter - surpassing its previous record-breaking second quarter."
|
PRPO | Hot Stocks09:08 EST Precipio appoints Christina Valauri to board of directors - Precipio welcomes Christina Valauri to its board of directors effective Jan 1st, 2024. Ms. Valauri brings a 30-year track record as a senior healthcare analyst and has held leadership roles that include US and Global Head of Equity Research and Managing Director at Cantor Fitzgerald, and senior equity research management roles at firms including ING, Credit Lyonnais, and Natixis. Valauri is the founding partner and CEO of Sagestone Advisory, LLC. After serving on Precipio's board of directors for 6 years, Douglas Fisher, MD is stepping off the board to maintain a board of 7 directors and will remain as an observer moving forward.
|
ADEX | Hot Stocks09:08 EST Adit EdTech Acquisition Cor trading halted, news dissemination
|
ONCT | Hot Stocks09:07 EST Oncternal Therapeutics reports inducement award under Nasdaq listing rule - Oncternal Therapeutics announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. The award will be made on January 2, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 19,500 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal's common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee's start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal's compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).
|
BAFN | Hot Stocks09:06 EST BayFirst Financial appoints Zernick as CEO, Oliver as President, COO - BayFirst Financial announced that its Board of Directors appointed Thomas Zernick as chief executive officer, CEO, and named Robin Oliver president and chief operating officer, COO, effective January 1, 2024. As previously announced, retiring Chief Executive Officer Anthony Leo will remain a director of the Company and will also serve as a part-time consultant for strategic matters .Zernick was made a director of the Company and joined the Board in February 2023 when he was appointed successor chief executive officer. He has served as president of the Company since February 2022. Oliver has held the role of chief operating officer of BayFirst since 20228.
|
TURN | Hot Stocks09:06 EST 180 Degree notes start of measurement period for Discount Management Program - 180 Degree Capital noted that today is the beginning of the first measurement period of its previously announced Discount Management Program established to reduce the discount that 180's common stock trades at versus its net asset value per share. As mentioned in 180's prior press release on November 13, 2023, under the terms of the Program, 180's Board of Directors have set two measurement periods of January 1, 2024, to December 31, 2024, and January 1, 2025, to June 30, 2025. Should 180's common stock trade at an average daily discount to NAV1 of more than 12% during either of these measurement periods, 180's Board will consider all available options including, but not limited to, a significant expansion of 180's current stock buyback program of up to $5 million, cash distributions, or a tender offer.
|
CCLD | Hot Stocks09:05 EST CareCloud announces strategic collaboration with Kovo HealthTech - CareCloud announced a strategic collaboration with Kovo HealthTech Corporation, a leader in healthcare technology and Billing-as-a-Service. This landmark partnership is designed to empower Kovo clients with an advanced suite of electronic health record solutions, cutting-edge practice management software, unparalleled credentialing support, and an integrated clearinghouse. "This partnership with Kovo is a strategic win-win, expanding CareCloud's reach to Kovo's 2,250 healthcare providers and 4.5 million patients through Kovo's established billing platform," said Justin Pierce, CareCloud's chief sales officer. "We gain recurring revenue from Kovo's SaaS contracts and also bolster Kovo's offerings with our EHR, practice management software, and credentialing support. This enhanced suite positions both companies for market dominance while streamlining financial processes and administrative tasks for healthcare providers, ultimately allowing them to focus on what matters most - delivering exceptional patient care."
|
SCLX | Hot Stocks09:04 EST Scilex estimates 2023 total product net sales $46.5M-$52.5M - The Company estimates that: ZTlido gross sales for the fiscal year ended December 31, 2023 were in the range of $145M to $150M, compared to $96M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 51% to 56%. ZTlido net sales for the fiscal year ended December 31, 2023 were in the range of $46M to $52M compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 21% to 37%. Total product gross sales for the fiscal year ended December 31, 2023 were in the range of $150M to $155M, compared to $96M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 56% to 61%. Total product net sales for the fiscal year ended December 31, 2023 were in the range of $46.5M to $52.5M, compared to $38M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
|
PIPR | Hot Stocks09:03 EST Piper Sandler announces Kate Clune as CFO - Piper Sandler Companies announced that effective January 1, 2024, Kate Clune became chief financial officer, CFO, at Piper Sandler. ,The firm previously announced in September that Clune would be assuming the CFO role from Tim Carter, who will remain with the firm through April to assist with the transition. Clune will oversee all financial operations of Piper Sandler, including leading the investor relations team. She will report directly to Chad Abraham, chairman and chief executive officer. Clune joins the firm from Evercore where she most recently served as treasurer and head of planning and strategy. She previously spent 16 years at Morgan Stanley, serving in various capacities across operations, sales and trading and finance. Her roles included corporate treasury and CFO of their U.S. banks, as well as global head of financial planning and analysis.
|
AZN | Hot Stocks09:03 EST AstraZeneca signs exclusive option and global license agreement with Allorion - AstraZeneca has entered into an exclusive option and global license agreement with Allorion Therapeutics, a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, to develop and commercialize a novel epidermal growth factor receptor - EGFR - L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer or NSCLC. AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500M, as well as tiered royalties on net sales worldwide.
|
FLEX NXT | Hot Stocks09:03 EST Flex completes spin-off of remaining interest in Nextracker - Flex (FLEX) announced the completion of the spin-off of all of its remaining interest in Nextracker (NXT) to Flex shareholders on a pro rata basis. Under the previously disclosed terms of the transaction, Flex shareholders received approximately 0.17 shares of Nextracker Class A common stock for every Flex ordinary share held as of the record date of December 29, 2023, with 74,432,619 shares of Nextracker Class A common stock issued to Flex shareholders in the aggregate. Flex shareholders will receive cash in lieu of any fractional shares. As a result of the completion of the spin-off, Flex no longer directly or indirectly holds any shares of Nextracker common stock or any securities convertible into or exchangeable for shares of Nextracker common stock. Flex ordinary shares will continue to trade on Nasdaq under the ticker symbol "FLEX" and shares of Nextracker Class A common stock will continue to trade on Nasdaq under the ticker symbol "NXT".
|
SNES | Hot Stocks09:01 EST SenesTech announces expanded distribution agreement for Evolve - SenesTech announces the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of Evolve. This expansion also extends the territory into the United Arab Emirates market through the Pesterminators subsidiary, TCS Global for General Trading LLC in UAE. "This expansion is part of our regional strategy as we collaborate with Pesterminators and follows the successful deployment of our ContraPest products into the Maldives. This expanded distribution agreement incorporates their initial stocking order for Evolve as well as an expanded territory that now includes the UAE," said Joel Fruendt, SenesTech's president and CEO.
|
RIVN | Hot Stocks08:54 EST Rivian Automotive down 5% at $22.20 after Q4 production data
|
NICH | Hot Stocks08:50 EST Nitches says company is in the 'final stages' of filing S1 - The company said, "Nitches is thrilled to recap its achievements in 2023 and announce exciting prospects for the upcoming year. In a pivotal move, Nitches Inc secured its official status by registering with the TTB, marking a significant milestone in the company's journey to bring unique alcohol brands to the market...Anticipation is high as Tover Spirits prepares for its debut in the Florida market in Q1, marking the beginning of an exciting journey to capture the hearts of consumers. In the realm of fashion, Nitches Inc achieved remarkable exposure, featuring its clothing at prestigious venues such as the ALSD, Lucas Oil Stadium, Gainbridge Fieldhouse, and the iconic Indianapolis Motor Speedway. The company showcased its dedicated team through captivating images and videos, offering an up-close and personal look at the individuals behind the scenes. Tover took center stage at an exclusive mansion event during the Fort Lauderdale International Boat Show, creating a buzz around the brand and leaving a lasting impression on attendees. Voodofe, a fashion designer and artist who designed the Miles Davis line under the Nitches umbrella, garnered attention as celebrities Robert Kennedy Jr, Donnel Rawlings, and Robby Krieger, guitarist for The Doors as well as many others flaunted the unique designs, adding a touch of glamour to high-profile events. Looking ahead to 2024, Nitches Inc is in the final stages of filing the S1, initiating the process of uplisting to a higher exchange. Discussions with several investors are progressing, and the company is poised to secure a more conventional and non toxic type of financing crucial for the launch and expansion of the Tover Whiskey brand. The company has also been in discussions regarding several other flavors and types of spirits that we plan to unveil throughout the upcoming year. Nitches Inc remains steadfast in its commitment to innovation, quality, and unparalleled experiences, setting the stage for another year of growth, success, and groundbreaking achievements."
|
GTLL | Hot Stocks08:48 EST Global Technologies enters LOI to acquire GOe3 - Global Technologies announced that the Company will expand its operations by entering into the EV space through its execution of a non-binding Letter of Intent to acquire GOe3. The LOI sets forth the proposed terms and conditions pursuant to which the Company and GOe3 intend to effect a business combination, as a result of which GOe3 will conduct business as a wholly-owned subsidiary of the Company. The Company anticipates that the Proposed Transaction will be structured as a share-for-share exchange, with the Company's shareholders retaining 30% and GOe3 receiving 70% of the combined Company. The Company will designate a new preferred stock to issue to the GOe3 members in exchange for the membership units. At Closing, Bruce Brimacombe will be named the Company's President and appointed to the Company's Board of Directors. Promptly following the closing, the Company will adopt a plan to apply for an uplist to a national exchange or the NASDAQ. The Proposed Transaction has been approved by the Board of Directors of the Company and the Managing Members of GOe3 and is expected to close in the first quarter of CY 2024. The Transaction will be considered a "reverse merger" because the members of GOe3 will own more than a majority of the outstanding common stock of the Company following completion of the Proposed Transaction.
|
KULR | Hot Stocks08:46 EST KULR Technology to introduce KULR ONE MAX at CES 2024 - KULR Technology announced the launch of KULR ONE MAX at the 2024 Consumer Electronics Show, this January 9-12, 2024. Attendees can experience the premiere of KULR ONE MAX showcased within the Energy Ark Storage Cabinet by NHOA.TCC, a subsidiary of publicly listed Taiwan Cement Corporation, at booth 4777 in the Las Vegas Convention Center - West Hall. This presentation will highlight KULR's dedication to pioneering safer and more cost-effective energy storage solutions. Building upon the Company's space-grade designed KULR ONE platform, the KULR ONE MAX emerges as the latest development for sectors including micro-mobility, defense, and aerospace. The design, rooted in KULR ONE Design Solutions, optimizes the use of 21700 cylindrical cells to support a robust Passive Propagation Resistant framework. This advancement ensures compliance with UL 9540 standards for thermal management without external fire suppression, enhancing safety and reducing costs.
|
TSLA | Hot Stocks08:43 EST Tesla reports Q4 deliveries 484,507, production of 494,989 vehicles - Tesla said: "In the fourth quarter, we produced approximately 495,000 vehicles and delivered over 484,000 vehicles. In 2023, vehicle deliveries grew 38% YoY to 1.81 million while production grew 35% YoY to 1.85 million." Tesla reported Q4 Model 3/Y deliveries of 461,538. For 2023, Tesla delivered 1.81M vehicles.
|
MYE | Hot Stocks08:42 EST Myers Industries to acquire Signature Systems in accretive deal - Myers Industries announced that it has entered into an Agreement and Plan of Merger through which it will acquire Signature Systems , a leader in composite ground protection solutions. Based in Flower Mound, TX with production operations in Orlando, FL, Signature's products are complementary to those sold by Myers. The company is a leading manufacturer and distributor of high-quality, branded composite ground protection products and is also a leading provider of turf protection solutions for stadiums and event venues in North America. Signature has projected 2023 revenue, operating income, and Adjusted EBITDA of approximately $122M, $24M and $44M, respectively. Myers will acquire Signature for a total consideration of approximately $350M, subject to customary adjustments. The transaction is expected to close in the first quarter of 2024 and to be neutral to slightly dilutive to US GAAP EPS in 2024, but then deliver EPS accretion of $0.20-$0.30 in 2025, $0.40 - $0.50 in 2026 and additional meaningful EPS accretion beyond 2026. Annualized run-rate operational and cost synergies of $8 million are expected to be fully captured by 2025. The transaction will be financed through a new $350 million credit facility. Projected net leverage ratio, as defined in the credit facility, is within Myers' strategy of having a net leverage ratio of approximately 3x at the time of acquisition, with combined free cashflow expected to allow for paydown to under 2x within two years of closing.
|
VEV | Hot Stocks08:41 EST Vicinity Motor signs VMC 1200 distribution agreement with Jack Carter - Vicinity Motor signed a new distribution agreement with Jack Carter Commercial Vehicles to open Jack Carter VMC Trucks, a new VMC specific dealership, by the owners of the successful Jack Carter Chevrolet Buick GMC Corvette Dealer for the Alberta South territory. With the opening of Jack Carter VMC Trucks, Jack Carter will provide fleet solutions for businesses and government with its inventory of VMC 1200 vehicles. Per the terms of the agreement, Jack Carter VMC Trucks will distribute Vicinity VMC 1200 trucks throughout Southern Alberta, inclusive of an initial order for 19 VMC 1200 vehicles.
|
AREC | Hot Stocks08:40 EST American Resources' ReElement appoints Kevin Higgins to board - American Resources Corporation's ReElement Technologies Corporation, announced the appointment of Kevin Higgins, a national security expert and former intelligence community senior executive who retired from the Central Intelligence Agency after 30 years of distinguished service, to its Board of Directors.
|
ONDS | Hot Stocks08:39 EST Ondas' American Robotics enrolls in Optimus System in Green UAS program - Ondas Holdings wholly owned subsidiary American Robotics has enrolled the Optimus System in the Green UAS program, a new program administered by the Association for Uncrewed Vehicle Systems. Through this program, and the related Trusted Cyber program, American Robotics will seek to certify the Optimus System as compliant with the highest levels of cybersecurity and supply chain requirements as outlined in the National Defense Authorization Act. By participating in the Green UAS program, American Robotics is looking to accelerate the acceptance of the Optimus System with commercial, state, and federal government agencies, including the Departments of Defense and Homeland Security.
|
RIVN | Hot Stocks08:39 EST Rivian Automotive produces 17,541 vehicles in Q4, 57,232 vehicles in FY23 - Rivian Automotive announced production totals for the quarter and full-year ending December 31, 2023. The company produced 17,541 vehicles at its manufacturing facility in Normal, Illinois and delivered 13,972 vehicles during the same period. On a full-year 2023 basis, the company produced 57,232 vehicles and delivered 50,122. This exceeded management's most recent full-year 2023 production guidance of 54,000 vehicles.
|
OGEN | Hot Stocks08:38 EST Odyssey Health closes asset sale with Oragenics - Odyssey Health announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, under which Oragenics acquired Odyssey's proprietary assets related to its neurological drug therapy platform under dvelopment. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C, as well as Odyssey's proprietary powder formulation and its nasal delivery device. Odyssey retains its other assets and operations. The Company received cash in two installments: $500,000 upon the execution of the Asset Purchase Agreement on October 4, 2023 and $500,000 on December 11, 2023, after Odyssey obtained its stockholders' approval for the asset sale at its special stockholder meeting held on December 7, 2023. At the Closing on December 28, 2023, Oragenics issued eight million shares of Oragenics' Series F Preferred Stock to Odyssey. On the day of the closing Oragenics' common stock last traded at $5.37 valuing the preferred stock at approximately $43M Certain members of Odyssey management joined Oragenics to lead the continued development of the pipeline of neurological drug therapies and technologies. Odyssey's technologies are expected to allow for easy nasal administration, rapid drug uptake to the brain, no cumbersome cold-chain protocols, and a strong safety profile, which hold potential to improve patient outcomes. The lead drug candidate, ONP-002 has the potential to be a first-in-class intranasal drug to treat moderate-to-severe concussion in the acute through subacute phases. In preclinical animal studies, the drug showed rapid and broad biodistribution throughout the brain while simultaneously reducing swelling, inflammation, and oxidative stress along with an excellent safety profile. Results from animals treated with the drug post-concussion showed positive behavioral outcomes using various testing platforms including improved memory and sensory-motor performance, and reduced anxiety. ONP-002 has completed a Phase 1human clinical trial showing it is safe and well tolerated in healthy human subjects. Oragenics are now preparing for Phase 2 clinical trials to further evaluate ONP-002's safety and efficacy.
|
VAL PBR | Hot Stocks08:38 EST Valaris in offshore drillship deal with Petrobras valued at $519M - Valaris Limited (VAL) announced that it has been awarded a 1,064-day contract for drillship VALARIS DS-4 with Petrobras (PBR) offshore Brazil following a competitive bidding process. Based on the firm contract term, the total contract value is approximately $519M, inclusive of mobilization fees and additional services. The contract is anticipated to commence late in the fourth quarter 2024, following completion of the rig's current contract with Petrobras, which is expected to finish in September 2024. Upon completion of its current contract, the rig is expected to be out of service for approximately 90 days to complete customer-required capital upgrades prior to commencement of the new contract. President and Chief Executive Officer Anton Dibowitz said, "We are delighted to have secured further work for drillship VALARIS DS-4 with Petrobras for their upcoming Buzios program and we look forward to continuing to partner with Petrobras on their programs offshore Brazil, a market where we expect to see continued growth over the next several years. We have previously stated that we expect Valaris' earnings and cash flow to increase meaningfully as rigs are recontracted at market rates. This contract award for VALARIS DS-4 is a great example of how we are executing on the operating leverage inherent in our business, with the rig repricing from a day rate in the low $200,000s to an effective day rate in the high $400,000s."
|
LE | Hot Stocks08:36 EST Land's End announces new term loan - Lands' End has entered into a new term loan of $260 million. The loan proceeds were used to refinance the Company's existing term loan well ahead of its maturity in September 2025. The loan is secured by a first lien on all non-ABL assets and a second lien on all ABL assets. Interest is payable monthly at an initial rate of 8.25% per annum plus the greater of SOFR or 2.0%. The initial rate is subject to a reduction to 8.00% and 7.75% based on the Company's debt and EBITDA levels. Amortization is payable quarterly at 1.25% of original principal amount. The loan matures in December 2028. The Company was advised on the refinancing transaction by Perella Weinberg Partners. The lending group includes Blue Torch Capital, Sculptor Capital Management, JPMorgan and Arbour Lane Capital Management.
|
BTCT | Hot Stocks08:36 EST BTC Digital purchases 2,000 units of T21 Miners - BTC Digital has entered into an asset purchase agreement with Bitmain Technologies to acquire 2,000 units of T21 Miners for $5,320,000. The machines are expected to be delivered and put into operation by the company in the first half of 2024. T21 is Bitmain's latest high-performance model, and the model's outstanding technical specifications make it an ideal choice for BTC Digital. After deploying the 2,000 units of newly acquired miners, the company expects to have a total of 4,174 units of miners under operation, with a total hash rate reaching 614PH/s, representing nearly three times of the combined hash rate of the machines owned by the company under operation as of today.
|
PXD | Hot Stocks08:36 EST Pioneer Natural CEO Richard Dealy commences role - Pioneer Natural announced that Richard Dealy has commenced his new role as CEO and Scott Sheffield has transitioned to the non-executive role of special advisor to the CEO, both effective January 1. As previously announced, Dealy succeeds Sheffield, who retired as CEO on December 31, 2023. Sheffield and Dealy will both continue to serve on the Pioneer board of directors.
|
KTTA | Hot Stocks08:35 EST Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004 - Pasithea Therapeutics announced the Investigational New Drug Application clearance to proceed by the U.S. Federal Drug Administration to evaluate PAS-004, a macrocyclic MEK inhibitor, in patients with MAPK pathway driven advanced solid tumors with a documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition. Pasithea expects to dose the first patient in the first quarter of 2024. The objectives of the dose escalation study are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics as well as anti-tumor responses of PAS-004 as monotherapy in up to 36 advanced cancer patients with preliminary early data expected as early as Q3 2024. Administered orally, PAS-004 is expected to be an once day or less frequent dose which may provide better compliance rates as well as superior efficacy. PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials. Macrocycles exhibit unique drug-like profiles because of their cyclic structure, potentially improving bioavailability, binding affinity, and overall pharmacokinetics in comparison to acyclic counterparts.
|
ELAN | Hot Stocks08:35 EST Elanco names Lawrence Kurzius as next Chairman of the Board - Elanco Animal Health announced that the Board of Directors has named Lawrence Kurzius as its next Chairman of the Board, effective at the conclusion of the company's 2024 Annual Meeting of Shareholders. Kurzius, a member of the Elanco Board since 2018, will succeed current Chairman, R. David Hoover, who will remain on the Board as an independent director.
|
SDIG | Hot Stocks08:35 EST Stronghold Digital mines 207 bitcoin in December - Stronghold mined 207 Bitcoin in December 2023 and generated approximately $0.4M in energy revenue, which represented the equivalent of approximately 9 additional Bitcoin based on the average price of Bitcoin during the month. This equated to approximately 216 of Bitcoin-equivalent production in December 2023, up approximately 2% sequentially compared to the Company's 212 Bitcoin-equivalent production in November. The Company generated an estimated $8.5M of revenue during the month of December, its highest monthly revenue in 2023. The driver of the sequential increase was a higher hash price of $0.10 in December compared to $0.08 in November. Drivers of the higher hash price were a 16% rise in average daily BTC price and higher transaction fees/block subsidies averaging 26% in December compared to 14% in November, partially offset by an increase in network hash rate of 6%.
|
CVX | Hot Stocks08:34 EST Chevron to impair part of U.S. upstream assets, sees up to $4B in charges - On January 2, Chevron Corporation announced that for fourth quarter 2023, "the Company will be impairing a portion of its U.S. upstream assets, primarily in California, due to continuing regulatory challenges in the state that have resulted in lower anticipated future investment levels in its business plans. The Company expects to continue operating the impacted assets for many years to come. In addition, the Company will be recognizing a loss related to abandonment and decommissioning obligations from previously sold oil and gas production assets in the U.S. Gulf of Mexico, as companies that purchased these assets have filed for protection under Chapter 11 of the U.S. Bankruptcy Code, and we believe it is now probable and estimable that a portion of these obligations will revert to the Company. We expect to undertake the decommissioning activities on these assets over the next decade.The Company is in the process of finalizing the financial impacts of these actions, which it expects to treat as special items and exclude from adjusted earnings. These actions in the aggregate are currently estimated to result in non-cash, after-tax charges of $3.5B to $4B in the Company's fourth quarter 2023 results," said the company in a regulatory filing. Reference Link
|
SDIG | Hot Stocks08:34 EST Stronghold Digital enters agreement to purchase 5,000 bitcoin miners - Stronghold Digital Mining executed agreements to purchase an aggregate of 5,000 Bitcoin miners on December 26, 2023, for approximately $8.5M. These miners are expected to provide Stronghold with approximately 600 PH/s of cumulative hash rate capacity with average efficiency of 25 J/T. The purchased miners include 2,800 new Bitmain S19K Pro miners purchased from Luxor Technology Corporation, 1,100 new MicroBT Whastminer M50 miners purchased from Luxor, and 1,100 new Avalon A1346 miners purchased from Canaan Creative Global. Stronghold funded the purchases with proceeds from the Company's recently announced private placement, and the delivery of all purchased miners is expected no later than January 2024. In addition to the purchase of the Avalon A1346 miners from Canaan, Stronghold was granted the option to purchase 2,500 Avalon A1466 miners any time between now and December 2024 for $12 per TH/s. The A1466 miners are expected to be available starting in April 2024.
|
CTXR | Hot Stocks08:33 EST Citius Pharmaceuticals completes enrollment in Phase 3 trial of Mino-Lok - Citius Pharmaceuticals announced that it has completed enrollment in its pivotal Phase 3 clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. A total of 109 catheter failure events were observed in the event-based trial; a minimum of 92 catheter failure events were required to complete the trial. The study enrolled 241 patients at clinical sites in the U.S. and India. Topline results are expected 2Q 2024.
|
IINN | Hot Stocks08:32 EST Inspira Technologies signs LOI with Chicago hospital for use of Inspira ART100 - Inspira Technologies has announced the signing of a non-binding Letter of Intent - LOI - with Northwestern Memorial Hospital in Chicago, Illinois. Northwestern is part of Northwestern Medicine, which operates several hospitals in the U.S. The LOI expresses the mutual interest by both parties to further explore potential collaboration regarding the evaluation of how the INSPIRA ART100 device aligns with Northwestern's needs in clinical scenarios, workflow efficiency, and healthcare delivery. Northwestern will also agree to purchase all necessary disposables to operate the Devices and will, in turn, provide Inspira Technologies with valuable data and Device diagnostics from its usage. The terms of the agreement contemplated by the LOI are subject to FDA clearance of the Device in the first half of 2024 as well as the parties entering a definitive evaluation agreement.
|
ATXI | Hot Stocks08:32 EST Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201 - Avenue Therapeutics announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy, SBMA, also known as Kennedy's Disease. AJ201 is currently the lead drug candidate in the clinic for SBMA, and topline data are anticipated in the second quarter of 2024. "We are pleased with the speed of enrollment in our Phase 1b/2a study evaluating AJ201 for the treatment of SBMA, reflecting the large unmet need in this debilitating neurodegenerative disease," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "We are intently focused on advancing this much needed drug for patients and their caregivers, and we look forward to reporting topline data in the second quarter of 2024."
|
CHRS | Hot Stocks08:32 EST Coherus Biosciences announces U.S. launch of LOQTORZI - Coherus BioSciences announced that LOQTORZI is now available through select specialty distributors in the United States. LOQTORZI is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a next-generation, programmed death receptor-1 monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor. NPC affects approximately 2000 patients in the U.S. annually. Until now the standard of care was chemotherapy. In December, the NCCN committee classified LOQTORZI as a preferred category 1 treatment option in combination with gemcitabine and cisplatin. The decision was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study. In the JUPITER-02 Phase 3 study, LOQTORZI combined with chemotherapy significantly improved progression-free survival, reducing the risk of disease progression or death by 48% compared to chemotherapy alone. LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in overall survival, with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone. In the POLARIS-02 clinical study, LOQTORZI demonstrated durable anti-tumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate of 20.5%, a disease control rate of 40.0%, and a median OS of 17.4 months with an acceptable safety profile. LOQTORZI is commercially available for purchase through select specialty distributors including Cencora, Cardinal and McKesson. Each carton contains one 240 mg/6 mL single-dose vial. Coherus expects a product-specific, permanent J-code to be assigned to LOQTORZI in mid-2024.
|
KOP | Hot Stocks08:32 EST Koppers Holdings names James Sullivan as President and COO - Koppers Holdings announced the election of James Sullivan as President and COO, effective January 1, 2024. Sullivan has been Executive Vice President and COO since January 2020. Leroy Ball will continue to serve as CEO of Koppers.
|
DXR | Hot Stocks08:31 EST Daxor submits dual 510k/CLIA-waiver application to FDA for Daxor BVA - Daxor Corporation announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration, FDA, via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company's mission is to advance healthcare by enabling optimal fluid management. "Today marks a long-anticipated and momentous milestone in our continued commitment to our customers, patients, and to achieving our vision of optimal blood volume for all," said Michael Feldschuh, Daxor's CEO and President. "Funded under contract by the U.S. Department of Defense, our next-generation analyzer will deliver a level of speed, access, and accuracy to blood volume management that can significantly improve care and outcomes in medicine."
|
VIA | Hot Stocks08:21 EST Via Renewables enters merger agreement for $11.00 per share in cash - Via Renewables has signed a merger agreement whereby all of Via Renewables' Class A common stock will be acquired by Retailco, LLC, a Texas limited liability company for $11.00 per share. The cash consideration represents a 17.0% premium to the closing share price of Via Renewables' Class A common stock on December 29, 2023, the last trading day prior to today's announcement and execution of the Agreement. The cash consideration also represents a 19.7% premium to the 30 trading-day volume-weighted average price as of December 29, 2023, and a 36.5% premium to the 60 trading-day volume-weighted average price as of December 29, 2023. Retailco is an entity owned by TxEx Energy Investments, LLC, which is wholly owned by William Keith Maxwell, III. Maxwell is Via Renewables' current Chief Executive Officer and Chairman of the Board and directly and indirectly owns approximately 65.7% of Via Renewables' common stock. The Agreement was negotiated and entered into following Via Renewables' receipt of proposals from Maxwell in which he expressed an interest in acquiring all shares of Via Renewables' Class A common stock that he did not currently hold. The transaction will be effected by a merger of NuRetailco LLC, a Delaware limited liability company and wholly owned subsidiary of Retailco, with and into Via Renewables, with Via Renewables surviving. Under the terms of the Agreement, all of Via Renewables' Class A common stock, except for shares of Class A common stock for which appraisal rights have been properly and validly exercised under Delaware law and certain additional shares, including those held by Via Renewables or any of its subsidiaries; Retailco or NuRetailco or any of their respective subsidiaries; or Maxwell, and any person or entity controlled by him, will be converted into the right to receive the cash consideration. The Class A common stock, currently traded under the symbol VIA, will cease to trade on NASDAQ upon consummation of the transaction. Via Renewables expects that its Series A Preferred Stock, currently traded under the symbol VIASP, will continue to trade on NASDAQ following the transaction. Accordingly, Via Renewables will remain subject to the reporting requirements of the Securities Exchange Act of 1934. The transaction was negotiated on behalf of Via Renewables by a Special Committee of its Board of Directors with the assistance of independent financial and legal advisors. The Special Committee is comprised of entirely disinterested and independent directors. Following the Special Committee's unanimous recommendation in support of the merger, Via Renewables' Board of Directors approved the Agreement and recommended that the Via Renewables' stockholders adopt and approve the Agreement and the merger. The Agreement provides for a "go-shop" period of thirty days following execution of the Agreement during which the Special Committee will be permitted to initiate, solicit or knowingly encourage and facilitate discussion for any inquiry, offer or request that could reasonably be expected to lead to a competing transaction with a third party. Maxwell has not forfeited his right to participate in any subsequent meeting of the Via Renewables' Board of Directors regarding a competing transaction or superior proposal. There can be no assurance that this "go-shop" process will result in a competing transaction or superior proposal. The merger is subject to approval by a majority of holders of the issued and outstanding shares of Via Renewables' Class A common stock and Class B common stock. In addition, the merger is subject to a non-waivable requirement of approval by the holders of at least a majority of the issued and outstanding Class A common stock and Class B common stock not owned by Maxwell and his affiliated entities or the directors, officers or their immediate family members. Maxwell and affiliated entities have entered into a support agreement to vote their shares in favor of the transaction and against any competing transaction. The Agreement is not subject to a financing condition, but is subject to customary closing conditions. The transaction is expected to close in the second quarter of 2024.
|
VTAK | Hot Stocks08:18 EST Catheter Precision receives patents for LockeT in Great Britain, Europe - Catheter Precision announced that Great Britain and the European Market have allowed two new patents, further strengthening the company's IP position for its LockeT product line. These new issued patents for LockeT are in addition to an issued patent in Japan earlier in 2023.
|
FIX | Hot Stocks08:17 EST Comfort Systems USA to acquire Summit Industrial, sees accretion - Comfort Systems USA announced that it has entered into a definitive agreement to acquire Summit Industrial Construction headquartered in Houston, Texas. The transaction is currently expected to close in the first quarter of 2024. Summit is a specialty industrial mechanical contractor offering engineering, design-assist and turnkey, direct hire construction services of modular systems serving the advanced technology, power, and industrial sectors. Initially, Summit is expected to contribute annualized revenues of approximately $360M to $400M, and earnings before interest, taxes, depreciation, and amortization of $30M to $45M. In light of the amortization expense, Summit is expected to make a neutral to slightly accretive contribution to earnings per share in 2024 and 2025.
|
XSNX | Hot Stocks08:16 EST NovAccess Global announces $10.7M financing - NovAccess Global entered into a securities purchase agreement with an affiliate of Sumner Global for a total financing of $10.7M. Pursuant to the agreement, Sumner agreed to purchase 33M newly issued shares of the Company's unregistered common stock at 11c per share, for a $3.63M cash investment payable on or before January 31, 2024, subject to a financing contingency. In addition, Sumner agreed to make an additional investment of $7.05M in the form of a convertible note in two tranches, with $3.05M on February 15, 2024, and the remaining $4M on March 15, 2024, subject to a financing contingency. These notes are convertible into common shares at 11c per share.
|
UGRO | Hot Stocks08:16 EST Urban-Gro secures design-build contract valued at approximately $20M - urban-gro announced that it has secured a design-build contract with an existing vertically integrated U.S.-based multi-state Cannabis cultivation and retail dispensary operator. The contract is for the design and construction of both a new cultivation facility and the interior retrofit of an existing facility. The contract is valued at approximately $20 million and it is anticipated that revenue will be recognized over the next six quarters. Bradley Nattrass, Chairman and CEO, commented, "Our turnkey approach coupled with our unique industry expertise allows us to streamline complex projects like this one by seamlessly integrating the design and construction phases. Not only does this simplify the client experience, but it significantly improves speed to market. Building on our business development efforts over the past year, it is rewarding for the team to kick off 2024 with a strong contract win. I remain optimistic that the Cannabis industry will experience increased momentum this year, and our team of nearly 140 professional service providers and horticulturalists will be ready to guide our clients through the next phases of their projects."
|
SPRO GSK | Hot Stocks08:15 EST Spero announces first patient, first visit for Phase 3 PIVOT-PO trial - Spero Therapeutics (SPRO) announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections, cUTI, including acute pyelonephritis. Spero is entitled to receive $95 million in development milestone payments from GSK (GSK), which is payable in four equal installments over two years. "First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program," said Sath Shukla, President and CEO of Spero Therapeutics. "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI. Oral administration may provide physicians with an alternative to hospital-based IV therapy, for appropriate patients, with potential value to the broader healthcare system."
|
ISRL | Hot Stocks08:14 EST Israel Acquisitions and Pomvom enter business combination to trade on NASDAQ - Israel Acquisitions and Pomvom, a technology company that develops experiential content to amusement parks and attractions globally, announced a definitive business combination agreement at a total equity value for Pomvom of $125M. The combined company will trade on the Nasdaq. Pomvom serves many theme park and attraction operators globally, including, parent companies Six Flags, Warner Bros. and Merlin Entertainment. Strategic long-term agreements signed in 2023 with Warner Bros. and Six Flags are expected to increase the number of partner sites for Pomvom to 47 sites by the end of 2024 - a 23% increase from its current 38 sites. Pomvom's launch of digital content across its partner sites is expected to leverage its new online platform and accelerate long-term growth. Pomvom revenues in 2022 were approximately $57.4M. Upon completion of the transaction, including the capital injection of at least $20M from the business combination, the company targets at least a 30% increase in top-line revenues, with a 2024 expectation of reaching a positive adjusted EBITDA. Pomvom shareholders holding a majority of the company's issued share capital will sign support agreements displaying support of the transaction within 30 days of the Business Combination Agreement. The combined company's Board of Directors will have up to 7 directors in the first stage, of which 2 directors will be nominated by ISRL and up to 5 directors will be nominated by the company. The parties anticipate completing the business combination by the end of Q3 2024. At the closing of the transaction, Pomvom will be delisted from the Tel Aviv Stock Exchange and listed solely on the Nasdaq in the U.S.
|
VISL | Hot Stocks08:14 EST Vislink appoints Bill Sweeney as managing director of MilGov business - Vislink Technologies announced the appointment of Bill Sweeney as the Managing Director of its MilGov business. His appointment is a strategic move following Vislink's acquisition of Broadcast Microwave Services assets in September 2023. He joins Vislink with over a decade of experience in roles that transformed Troll Systems Corporations and Broadcast Microwave Service
|
ALIM ORGS | Hot Stocks08:13 EST Alimera Sciences names Maltz as Chief Financial Officer - Alimera Sciences (ALIM) announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately. Most recently Maltz was the Chief Financial Officer with Orgenesis (ORGS), a publicly traded global biotech company transforming the processing of cell and gene therapies. Maltz will be taking on the role from Russell Skibsted. Skibsted's departure is not the result of any disagreement with management concerning the Company's operations or management. The Company also announced today that on January 2, 2024, in connection with Maltz's joining as Chief Financial Officer, the Compensation Committee of the Board of Directors of the Company approved an inducement option to purchase up to 75,000 shares of common stock to Maltz.
|
AVXL | Hot Stocks08:12 EST Anavex provides update on Rett Syndrome Program - Anavex Life Sciences reported topline results from the randomized, double-blind, placebo-controlled, Phase 2/3 EXCELLENCE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX2-73 in 92 pediatric patients with Rett syndrome between the ages of 5 through 17 years. This was the very first study of ANAVEX2-73 in pediatric patients with Rett syndrome. After 12 weeks, the study showed improvement on the key co-primary endpoint Rett Syndrome Behaviour Questionnaire, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients' caregivers. The other co-primary endpoint, the Clinical Global Impression - Improvement scale, which represents a less granular assessment by the site investigators using a seven-point scoring, was not met. In an ad-hoc analysis, using the predefined mixed-effect model for repeated measure method, after 12 weeks of treatment, ANAVEX2-73-treated patients improved LS Mean -12.93 points on their RSBQ total score compared to LS Mean -8.32 points in placebo-treated patients. The LS Mean difference of -4.65 points between treated and placebo groups was statistically significant. When looking at other placebo-controlled Rett syndrome trials, ANAVEX2-73 compares favorably in terms of absolute RSBQ improvements, with the caveat that cross trials comparisons have their limitations. The key secondary endpoint, the Anxiety, Depression, and Mood Scale, trended favorably. In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively, the RSBQ and ADAMS demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors and social avoidance. In the EXCELLENCE study, a large placebo effect was observed which may have masked the compound's therapeutic effect. Anavex believes to have identified the probable causes. A preliminary review of the safety results indicates there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX2-73 to date. The most common treatment-related adverse events in the drug-treated group were somnolence and lethargy and were predominantly mild to moderate in severity. There were no clinically meaningful changes observed in SAEs associated with known risks of ANAVEX2-73. Over 91% of patients completing the trial continued into a 48-week open-label extension study, which is ongoing.
|
CMG | Hot Stocks08:10 EST Chipotle announces partnership with Strava - Chipotle Mexican Grill announced a partnership with Strava, a digital community for active people with more than 120M athletes, to encourage and reward healthy habits this year. Chipotle is the first restaurant brand to build a customized challenge and segments on Strava, which will reward determined athletes with a chance at free Lifestyle Bowls.
|
SOTK | Hot Stocks08:09 EST Sono-Tek announces transition of Coccio to Chair, appoints Harshbarger to CEO - Sono-Tek Corporation announced that it has completed the senior management transition that was previously announced at the Company's most recent annual meeting on August 24, 2023. Effective as of December 31, 2023, Dr. Christopher Coccio transitioned from his position as Chief Executive Officer of Sono-Tek Corporation to the Company's Executive Chairman. He will also continue to serve as Chairman of the Company's Board of Directors. As Executive Chairman, Dr. Coccio will continue to play a senior leadership role in the Company's management. Effective upon Dr. Coccio's transition, the Board formalized the appointment of R. Stephen Harshbarger as the Company's Chief Executive Officer. He will also remain President, a position he has held since 2012.
|
PLSE | Hot Stocks08:08 EST Pulse Biosciences submits 510K to FDA for CellFX nsPFA cardiac clamp - Pulse Biosciences announced the filing of a premarket notification 510k to the U.S. Food and Drug Administration FDA for its novel CellFX nsPFA Cardiac Clamp. "The comparative preclinical data included in this 510(k) submission clearly demonstrates the highly differentiated safety and performance benefits of nsPFA in cardiac ablation and its potential benefit to patients and physicians. The speed and precision of delivery and the quality of the lesions, independent of tissue type or thickness, along with the impressive safety profile are unique, and I expect will drive many cardiac surgeons like me to start utilizing the CellFX nsPFA Cardiac Clamp for their patients," said Dr. Niv Ad, Chief Science Officer, Cardiac Surgery of Pulse Biosciences. "We look forward to sharing the preclinical dataset in upcoming scientific meetings and to collaborating with the FDA throughout its review process as we advance the clamp towards clinical use."..."We are beyond excited to start 2024 with another milestone in the Company's progress into the cardiac market. We expect the CellFX nsPFA Cardiac Clamp will demonstrate the superior safety and effectiveness of nsPFA for cardiac ablation in cardiac surgery and will serve as an entry point into this large and growing market. Along with our CellFX nsPFA 360 Cardiac Catheter, we plan to surround cardiac care teams with next generation nsPFA technology to drive better patient outcomes," said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences
|
SLGC | Hot Stocks08:07 EST SomaLogic issues letter to stockholders in favor of pending merger with Standard - SomaLogic sent an open letter to stockholders urging them to vote "for" the transaction with Standard BioTools. Highlights of the letter include: "Our upcoming special meeting of SomaLogic stockholders to vote on the merger with Standard BioTools is fast approaching. The SomaLogic Board believes that voting "FOR" the transaction represents the best opportunity available to maximize the value of your investment in SomaLogic. The transaction is the result of a months-long, thoughtful, fully informed review by our independent Board...this has been confirmed by both leading independent proxy advisory firms, ISS and Glass Lewis, recommending SomaLogic stockholders vote "FOR" the pending transaction...Benefits of Combination with Standard BioTools: ...increased scale and diversification...a robust and more diversified portfolio of life science tools; a stronger financial profile and enhanced operating leverage, with over $180M of pro-forma combined revenue, over $500M of cash, and only $68M of debt; $80M in anticipated run-rate cost synergies achieved by 2026; a combined Board and leadership team that brings together complementary teams with proven experience: SomaLogic stockholders will own 57% of the combined company...SomaLogic publicly announced the initiation of its strategic review process in March 2023, which has provided ample opportunity over the last ten months for any potential strategic or financial partner to emerge...Broad outreach included direct contact with 16 parties; only one party other than Standard BioTools entered into an NDA...Madryn Asset Management has issued misleading public commentary regarding the merger...they are waging a campaign to prioritize their own interests at the expense of other SomaLogic stockholders...Not voting is the same as voting against the transaction...The SomaLogic board urges all stockholders to vote "FOR" the value maximizing transaction on the SomaLogic proxy card today. SomaLogic stockholders are advised to discard any green proxy cards they receive from Madryn Asset Management, LP."
|
BIOR AZN | Hot Stocks08:07 EST Biora Therapeutics progresses research collaboration for BioJet platform - Biora Therapeutics (BIOR) announced that its BioJet Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca (AZN). The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption. "We continue to generate very promising results with our BioJet platform, including those from this study, which are enabling us to progress development under the collaboration," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "While many organizations have been working to solve the challenge of oral delivery of large molecules, we believe our approach stands out because of our ability to deliver multi-milligram liquid doses similar to injection, with minimal to no formulation changes."
|
STER | Hot Stocks08:07 EST Sterling Check acquires Vault Workforce Screening, terms not disclosed - Sterling Check has acquired Vault Workforce Screening, a U.S. clinic management platform. The acquisition brings a network of 17,000 clinics and a flexible service model to enhance Sterling's existing drug and health services. This will enable Sterling to deliver additional market leading screening solutions for employers in healthcare, transportation, and other regulated industries where staffing challenges are most acute, decreasing time-to-hire and improving employee retention. As part of Sterling's strategy to in-source key components of its supply chain, the acquisition of Vault will accelerate and strengthen Sterling's financial model and revenue growth. Vault's proprietary service model, including Medical Review Officer services and emergency/after-hours scheduling, will bring increased flexibility and control over delivery of drug and clinical services. This will enhance Sterling's suite of pre- and post-employment drug and health solutions, benefiting both Sterling and Vault clients. The acquisition is expected to contribute $40 to 50M of annualized revenue to Sterling and be accretive to Sterling's Adjusted EPS in 2024. Sterling expects to realize significant financial synergies related to vendor consolidation and pricing optimization, enhanced fulfillment capabilities, and operational efficiencies. Vault's expert management team and employees will transition to Sterling as the integration process moves forward and build upon the company's proven model of providing deep market expertise and unrivaled client service.
|
ESTA | Hot Stocks08:06 EST Establishment Labs reports first U.S. commercial use for Motiva Flora SmoothSilk - Establishment Labs announced that the Motiva Flora SmoothSilk Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery.
|
INMB | Hot Stocks08:06 EST INmune Bio doses first patient in Phase 1/2 study of INKmune - INmune Bio dosed the first patient in the Phase I/II trial in men with metastatic castration-resistant prostate cancer on December 27, 2023. INKmune is a biologic therapy given as out-patient therapy without the need for pre-medication or cytokine support. "Results of immunotherapy trials for mCRPC have been disappointing," said Professor Matt Rettig, Professor of Medicine and Urology, Medical Director of the Prostate Cancer Program at the David Geffen School of Medicine at UCLA and member of the Jonsson Comprehensive Cancer Center. "After many failures using T-cell focused immunotherapy approaches, targeting NK cells -- which are abundant in the prostate cancer tumor microenvironment -- is a promising and novel strategy. I am optimistic about the therapeutic potential of INKmune, an off-the-shelf innate immune therapy." Professor Rettig was deeply involved in the design of the clinical trial. Dr. Rettig's statements should not be construed as endorsement by the University of California.
|
ATAI | Hot Stocks08:05 EST Atai Life Sciences announces topline results from phase 1 study of EMP-01 - atai Life Sciences announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA. The goals of this Phase 1 study were to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EMP-01. The four-cohort, single-ascending dose, randomized, double-blind, placebo-controlled study enrolled 32 healthy participants who received 75mg, 125mg, 175mg or 225mg of EMP-01 or placebo in a 6+2 design. EMP-01 was well-tolerated, and treatment-related adverse events were all expected and generally dose dependent. There were no study discontinuations, and no serious or severe AEs were observed in the study. Non-clinically significant increases in blood pressure and heart rate were observed, though such changes showed limited dose dependency. Further, the peak body temperatures observed fell within the normal range. Finally, bruxism was observed in only 1 of 24 subjects that received EMP-01. The PK profile of EMP-01 was dose-proportional. The PD measures included both subjective reports and blood-based biomarkers. Significant, consistent and dose-dependent changes were seen on several of these exploratory PD measures. EMP-01 administration resulted in a differentiated subjective experience compared to racemic MDMA on standard psychedelic experience questionnaires.
|
CORT TEVA | Hot Stocks08:05 EST Corcept Therapeutics says court finds patents not infringed - Corcept Therapeutics (CORT) announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals (TEVA) does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering Korlym with drugs that are strong CYP3A4 inhibitors. "This disappointing decision is based on legal and factual errors we are confident will be reversed on appeal," said Joseph K. Belanoff, MD, Corcept's CEO. "Our patents describe medical discoveries that have greatly expanded the therapeutic options available to patients suffering from Cushing's syndrome, which is why the FDA added them to Korlym's prescribing instructions. Doctors have followed these instructions and will continue to do so to safely treat patients. Failure to recognize the novelty and import of discoveries like these would fundamentally change the law, to the detriment of the many patients whom innovative companies seek to serve. We will pursue our appeal vigorously," added Dr. Belanoff, "and will continue to assert our intellectual property rights whenever they are infringed."
|
LBPH | Hot Stocks08:05 EST Longboard Pharmaceuticals announces topline data from bexicaserin study - Longboard Pharmaceuticals announced topline data from the PACIFIC Study evaluating bexicaserin, a highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies, or DEEs. In the innovative PACIFIC Study, 52 participants ages 12-65 years old with a DEE diagnosis were enrolled at 34 study sites across the United States and Australia to evaluate the safety, tolerability, efficacy and pharmacokinetics of oral bexicaserin three times dail, or TID, versus placebo. Participant DEE diagnoses included DS, LGS, and other qualifying DEEs. Following a 5-week screening period and baseline evaluations, study participants initiated a dose titration over a 15-day period and subsequently continued on the highest tolerated dose throughout the maintenance period of 60 days. Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin and 9 to placebo. The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group. Participants were able to remain on a contemporary, stable polytherapy regimen of up to 4 anti-seizure medications, or ASMs, throughout the study, with the most common ASMs being clobazam, cannabidiol, lamotrigine and levetiracetam. The median change in countable motor seizure frequency from baseline for the evaluable participants treated with bexicaserin was a decrease of 53.3%, compared to a 20.8% decrease for those receiving placebo. Overall, this represents a placebo-adjusted reduction in seizure frequency of 32.5%. The median change in countable motor seizure frequency from baseline in the DS, LGS and DEE Other cohorts was a decrease of 72.1%, 48.1% and 61.2%, respectively. This represents a placebo-adjusted reduction in seizure frequency of 27.3% and 28.6% in LGS and DEE Other, respectively. Bexicaserin exhibited favorable safety and tolerability results. Most participants in the bexicaserin treated group that started the maintenance period tolerated the highest dose. The most common adverse events observed were somnolence, decreased appetite, constipation, diarrhea and lethargy. There were 3 participants that reported a serious adverse event (SAE) (ankle fracture, constipation, increased seizures) and no deaths were reported in the study. Overall, 9 participants in the bexicaserin group discontinued due to an AE. Of note, 2 of these participants discontinued during the maintenance period (7 participants discontinued during the titration period). No participants in the placebo group discontinued or experienced an SAE. 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study. Additional data from the PACIFIC Study are intended to be presented at future medical meetings.
|
ALUR | Hot Stocks08:05 EST Allurion Technologies expands deal with Weight Doctors, hires Brian Conyer - Allurion Technologies announced an expanded commercial agreement with Weight Doctors -Germany's leading group of private clinics and centers for weight loss-and the hiring of Brian Conyer to lead commercialization of Allurion's rapidly growing digital assets. After a successful 2023 in which it managed over 2,000 patients on Allurion's Virtual Care Suite VCS digital platform, Weight Doctors has signed with Allurion to expand usage of VCS across new patients and locations in 2024, including the Netherlands and the UK. The end patients include not only those treated with the Allurion Balloon, but also those receiving bariatric surgery and taking GLP-1 anti-obesity medications. The expanded agreement illustrates the momentum Allurion is seeing with its Virtual Care Suite and is an example of the growing pipeline of commercialization opportunities for Allurion's digital platform since launching Coach Iris-Allurion's 24/7 AI-powered weight loss coach-in October 2023. "As interest in weight loss has grown globally, the need for scalable digital solutions to manage patients and streamline workflow for providers has grown exponentially," said Shantanu Gaur, Founder and CEO of Allurion. "We believe digital solutions will benefit significantly from the rapidly expanding market opportunity in weight loss, and we aim to leverage our decade of expertise to be at the forefront with customers. Our growth with Weight Doctors underscores the power that Allurion's digital platform and suite of AI tools have in fulfilling this need for clinics serving large volumes of patients."
|
JSPR | Hot Stocks08:03 EST Jasper Therapeutics to effect 1-for-10 reverse stock split - Jasper Therapeutics announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 12:01 a.m. Eastern Time on Thursday, January 4, 2024. Jasper's voting common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, January 4, 2024. Following the reverse stock split, Jasper's voting common stock will continue to trade on the Nasdaq Capital Market under the symbol "JSPR" with a new CUSIP number of 471871202. The CUSIP number for Jasper's publicly traded warrants will not change. At the effective time of the reverse stock split, every ten shares of Jasper's issued and outstanding voting common stock will be automatically converted into one issued and outstanding share of voting common stock without any change in the par value of $0.0001 per share. This will reduce the number of issued and outstanding shares of common stock from approximately 111.6 million to approximately 11.2 million. The reverse stock split will not change the authorized number of shares of Jasper's voting common stock. No fractional shares will be issued in connection with the reverse stock split, and stockholders that would otherwise be entitled to a fractional share will instead receive a cash payment in lieu thereof equal to such fraction multiplied by the closing sales price of Jasper's voting common stock as reported on the Nasdaq Capital Market on January 3, 2024.
|
EDAP | Hot Stocks08:02 EST EDAP TMS appoints Ken Mobeck as global CFO, Francois Dietsch as global CAO - EDAP TMS announced that the Company has appointed Ken Mobeck as its CFO of EDAP worldwide, and Francois Dietsch as Global CAO. Both appointments are effective as of January 1, 2024.
|
SEEL | Hot Stocks08:01 EST ISS urges Seelos Therapeutics holders to vote 'FOR' all proposals at meeting - Seelos Therapeutics announced that Institutional Shareholder Services recommends Seelos stockholders vote "FOR" all proposals at the Special Meeting of Stockholders, including management's proposal to increase the number of authorized shares of common stock. The Special Meeting is scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024SM, on Wednesday, January 10, 2024 at 8:00 a.m., Eastern Time.
|
BTTX | Hot Stocks07:51 EST Better Therapeutics submits breakthrough device application for PDT - Better Therapeutics announced it has submitted a request to the FDA for breakthrough device designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as NAFLD and NASH.
|
HTHT | Hot Stocks07:45 EST H World Group CFO Jihong He steps down to serve as CSO - H World Group announced that Ms. Jihong He will step down as the CFO of the company and serve as the CSO of the Company, effective from January 2, 2024. Mr. Jun Zou, the executive vice president of the Company, has been appointed as the CFO of the Company, effective from the same date.
|
KAI | Hot Stocks07:42 EST Kadant completes acquisition of Key Knife for $156M in cash - Kadant has completed its previously announced acquisition of Key Knife and certain of its affiliates for approximately $156M in cash, subject to certain customary adjustments. The acquisition was financed primarily through borrowings under Kadant's revolving credit facility. Key Knife is a global supplier of engineered knife systems for custom chipping, planing, and flaking solutions for wood product industries. Its products enable wood processing mills to improve fiber recovery, product quality, and maximize production while lowering operating costs. The company is headquartered in Tualatin, Oregon with 141 employees located primarily in the United States and Canada. Key Knife's revenue for the trailing twelve months ended September 30, 2023 was approximately $65M. Key Knife will become part of Kadant's Industrial Processing reporting segment.
|
ASA | Hot Stocks07:38 EST ASA adopts limited duration rights plan amid Saba acquisition of 17% stake - The Board of Directors of ASA Gold and Precious Metals has unanimously adopted a limited-duration shareholder rights plan to protect the interests of the Company and all of its shareholders. The Rights Plan is currently effective and will expire on April 29 . The limited-duration Rights Plan was adopted in response to the rapid and significant accumulation of ASA shares by Saba Capital Management. In recent public filings, Saba disclosed that it and its affiliates have acquired a position in ASA representing 16.87% of ASA's outstanding common shares. The Rights Plan is intended to prevent Saba's unilateral attempt to obtain creeping control of the Company, which the Board believes would undermine ASA's strategic focus on long-term capital appreciation in the global gold mining industry. The Rights Plan is designed to enable ASA's shareholders to realize the long-term value of their investment, provide an opportunity for all shareholders to receive fair and equal treatment in the event of any proposed takeover of ASA and guard against tactics to gain control of ASA without paying all shareholders, what the Board considers to be an appropriate premium for that control. The Rights Plan is not intended to deter offers or preclude the Board from taking action that it believes is in the best interest of the Company and its shareholders. ASA will issue one right for each ASA common share outstanding as of the close of business on January 12 . The rights will initially trade with ASA's common shares and will become exercisable only if a person acquires 15% or more of ASA's outstanding common shares.
|
SNGX | Hot Stocks07:33 EST Soligenix anounces publication showing efficacy of ebolavirus and MARV vaccine - Soligenix announced a publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus - SUDV - and Marburg marburgvirus - MARV - infections. The manuscript has been published in Vaccine. This vaccine candidate has been previously demonstrated to be stable to high temperature storage for at least 2 years at 40 degrees Celsius. There are currently no approved vaccines or therapeutics for either SUDV or MARV infections. The published paper describes the potency of the bivalent formulation against both viruses, demonstrating 100% protection in the most rigorous non-human primate challenge models. The thermostabilized filovirus vaccine program is continuing to advance with the support of a National Institute of Health grant awarded to UHM and a Small Business Innovation Research grant awarded to Soligenix.
|
APCX | Hot Stocks07:33 EST AppTech Payments says Reno International Airport adopts FinZeo platform - AppTech Payments announces Reno International Airport as the first international airport to adopt its newly acquired FinZeo platform, which manages all financial transactions and payments within the airport's facilities. The Company anticipates additional airports to fully adopt the platform in the coming weeks.
|
STRM | Hot Stocks07:32 EST Streamline Health expands agreement with existing eValuator client - Streamline Health Solutions announced that it has expanded an existing contract with a 6 facility, Oracle Cerner-EHR based health system. The system has been using eValuator for pre-bill code auditing for more than 3 years and has elected to add RevID's automated charge reconciliation for improved pre-bill revenue integrity. The client also added the eValuator Pro Fee module and extended the term of the overall agreement for an additional 3 years. "We are thrilled our client is expanding their ability to ensure accurate compensation for all of the care they've provided through our industry leading solutions" stated Ben Stilwill, President and Chief Executive Officer, Streamline. "We are confident that bringing together RevID's charge reconciliation and eValuator's pre-bill code audting technology in one health system will have a synergistic impact, resulting in significant improvements to this system's revenue cycle. We look forward to sharing the results of this first enterprise client with our existing clients and prospects."
|
XOMA | Hot Stocks07:32 EST Xoma board authorizes $50M stock repurchase program - XOMA Corporation announced its Board of Directors has authorized XOMA's first stock repurchase program, which permits the Company to purchase up to $50M of XOMA's common stock through January 2027.
|
THTX | Hot Stocks07:32 EST Theratechnologies submits sBLA for Trogarzo IM method of administration to FDA - Theratechnologies announced that the Company has filed a supplemental Biologics License Application, sBLA, for an intramuscular, IM, method of administration for the maintenance dose of Trogarzo to the United States Food and Drug Administration, FDA, for review. In the U.S., Trogarzo, in combination with other antiretrovirals, ARVs, is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen. "The intramuscular method of administration, if approved for the maintenance dose, will give patients and their health care providers more options for Trogarzo treatment and without the need for regular IV placement," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "Our vision through the introduction of IV push administration and, hopefully soon, IM administration, is that Trogarzo treatment will be a less invasive and more convenient proposition for heavily treatment-experienced adults with HIV, a population that has long had limited non-oral treatment options."
|
CORT TEVA | Hot Stocks07:31 EST Corcept sinks after judge rules for Teva in Korlym patent case - Teva Pharmaceuticals (TEVA) won a patent infringement lawsuit against Corcept Therapeutics (CORT) on Friday relating to Concept's Cushing syndrome treatment Korlym. Corcept "has not demonstrated that there is a likelihood of direct infringement of the asserted claims in the future because it has not established that physicians are likely to coadminister mifepristone with a strong CYP3A inhibitor at an infringing sequence and/or dosage now or in the future," Judge Renee Marie Bumb wrote in an opinion late Friday. "Indeed, Corcept failed to introduce credible record evidence that anyone has ever previously infringed the asserted claims," according to the judge. Shares of Corcept Therapeutics are down 33% to $21.75 in premarket trading.
|
DISH SATS | Hot Stocks07:25 EST Dish Network convertible notes become convertible into shares of EchoStar - DishNetwork (DISH) announced that, in connection with the closing of the merger between Dish and EchoStar (SATS) on December 31, 2023, as a result of which Dish survived the merger as a wholly owned subsidiary of EchoStar, Dish's 2.375% Convertible Notes due 2024, 0% Convertible Notes due 2025 and 3.375% Convertible Notes due 2026 have become convertible into shares of EchoStar Class A common stock, par value $0.001 per share. The Notes were previously convertible into shares of Dish Class A common stock, par value $0.01 per share. Upon the closing of the merger, each then-outstanding share of Dish Common Stock was converted into the right to receive 0.350877 shares of EchoStar Common Stock, resulting in an adjusted Conversion Rate of 4.2677 for the 2024 Notes, 8.5657 for the 2025 Notes and 5.3835 for the 2026 Notes. As a result of the merger, holders of the Notes may surrender all or any portion of their Notes for conversion at any time from or after the open of business on January 2, 2024 until the close of business on the 35th Trading Day after the date of the merger, which is expected to be February 21, 2024. In addition, holders of the 2024 Notes currently have the right to surrender all or any portion of their Notes for conversion at any time prior to the close of business on the second Scheduled Trading Day immediately preceding March 15, 2024.
|
THR | Hot Stocks07:10 EST Thermon Group acquires Vapor Power, terms not disclosed - Thermon Group acquired Vapor Power International and its affiliates, a provider of high-quality industrial process heating solutions. Vapor Power realized revenue of over $50M in the calendar year ended December 31, 2023. Thermon expects the transaction to be accretive to GAAP earnings per share in the first twelve months. The acquisition was funded with cash on hand and an expanded term loan under Thermon's existing credit agreement. Thermon acquired Vapor Power from an investment group led by Stone Pointe and members of Vapor Power's management team.
|
GAME | Hot Stocks07:09 EST GameSquare completes sale of non-core radio business assets - GameSquare Holdings has completed the sale of its Frankly non-core radio business assets to SoCast. As a result of the $3.4M asset sale, GameSquare has added non-dilutive capital to its balance sheet. GameSquare also announced that it has further strengthened its balance sheet by refinancing the Company's convertible debt. GameSquare has retired a principal amount $5M debenture that was due to mature in February of 2024, and replaced it with a principal $5.8M convertible note issued to an arm's length party that bears interest at 12.75%, has a two-year term, and is convertible at the holder's option into common shares of Company at a price of $5 per share. The issuance of the debenture has been conditionally approved by the TSX Venture Exchange.
|
VIRI | Hot Stocks07:07 EST Virios reaches alignment with FDA on requirements for IMC-2 advancement - Virios Therapeutics announced receipt of the Food and Drug Administration's feedback on requirements for advancing IMC-2 as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC illness, also known as post-acute sequelae of SARS-CoV-2 infection. Key Highlights Associated with FDA Feedback: The FDA agreed that for the planned Phase 2 proof-of-concept study, Virios can use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint to assess the effectiveness of IMC-2 in treating PASC. The FDA recommended assessment of a range of IMC-2 doses, including valacyclovir doses above presently approved dosage strengths, to ensure effective inhibition of reactivated herpesvirus. Following the receipt of the FDA's feedback, Virios is currently exploring options to advance the IMC-2 LC Phase 2 research program. IMC-2 has the potential to be one of the first approved treatments specifically for LC.
|
SKYT | Hot Stocks07:07 EST SkyWater Technology submits application to CHIPS for funding - SkyWater Technology announced it has submitted a full application to the CHIPS Program Office of the U.S. Department of Commerce for funding through the CHIPS and Science Act. The application is for modernization and equipment upgrades to enhance production at the company's Minnesota DOD Trusted semiconductor manufacturing facility. SkyWater is now planning for the next phases of due diligence with federal and state partners' program offices.
|
SNDX | Hot Stocks07:06 EST Syndax says sufficient cash runway to fund operations through 2026 - In the fourth quarter of 2023, Syndax issued 12,432,431 shares of its common stock at $18.50 per share. Additionally in the quarter, the company sold 2,719,744 shares from its ATM facility. Aggregate net proceeds from these offerings were approximately $258.1M after deducting underwriting discounts and commissions and estimated offering expenses payable by Syndax. With these proceeds, the company now believes that it has sufficient cash runway to fund its clinical and commercial operations through 2026. "With positive pivotal data readouts for both revumenib and axatilimab and subsequent presentations at the American Society of Hematology Annual Meeting, 2023 was truly a landmark year for Syndax," said Michael Metzger, CEO. "We are working with the FDA during their review of our regulatory submissions while diligently preparing for the potential launch of two first- and best-in-class products in the U.S. in 2024. We look forward to continuing to broadly expand revumenib and axatilimab beyond their first approvals and into additional indications which have the potential to deliver meaningful clinical benefit."
|
IMCC | Hot Stocks07:06 EST IM Cannabis concludes planning and construction legal proceedings against Focus - IM Cannabis is announcing that the construction proceedings against Focus Medical Herbs were concluded on December 28, 2023. The company maintains "de facto" control of Focus Medical. Focus Medical was indicted and a fine of C$129K has been imposed. The cultivation facility, which was the focus of the proceedings, was closed in June 2022 in alignment with the company's strategic shift towards import and sales.
|
ADEX GRDI | Hot Stocks07:05 EST Griid Infrastructure lists on Cboe Canada after completing business combination - GRIID Infrastructure Inc. (GRDI) announced the listing of its common stock on Cboe Canada. As previously announced, the business combination was approved by Adit EdTech (ADEX) stockholders on November 30, 2023, during a special meeting of Adit EdTech stockholders, and the transaction closed on December 29, 2023. GRIID's common stock will begin trading on Cboe Canada, formerly known as the NEO Exchange, at market open on January 2, 2024, under the ticker symbol "GRDI" for GRIID's common stock, and GRIID is seeking to list its common stock and warrants on a U.S. exchange. GRIID is a purpose-built bitcoin mining company, founded in 2018, that has operated mining facilities since 2019. GRIID has built long-term power relationships securing affordable, reliable, environmentally responsible power, enabling a vertically integrated self-mining business model with significant growth opportunity. The combined company, which has been renamed GRIID Infrastructure Inc., will continue to be led by Founder, Chairman and CEO Trey Kelly. David Shrier, former CEO of Adit EdTech, has joined GRIID's Board of Directors. The business combination is intended to help GRIID to accelerate its core growth strategies and the expansion of its mining facilities throughout the United States. GRIID currently has four mining facilities in the United States in Watertown, New York and Limestone, Maynardville and Lenoir City, Tennessee.
|
LPTX | Hot Stocks07:05 EST Leap Therapeutics completes enrollment of DKN-01 trial in gastric cancer - Leap Therapeutics announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer. Part C of the DisTinGuish study is a Phase 2, randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab and chemotherapy in first-line patients with advanced gastroesophageal adenocarcinoma. Part C enrolled 170 first-line, HER2-negative patients. Patients were randomized 1:1 to evaluate DKN-01 in combination with tislelizumab and standard of care chemotherapy, compared to tislelizumab and SOC chemotherapy alone. The primary objective is progression-free survival in DKK1-high and in all patients. Secondary objectives of Part C include overall survival and objective response rate as measured by RECIST v1.1 in DKK1-high and in all patients.
|
CLGN | Hot Stocks07:05 EST CollPlant begins trial of commercial-size, regenerative breast implants - CollPlant Biotechnologies announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast. "We are very happy with the progress of our regenerative breast implants program thus far, and the initiation of this important study," said CollPlant's CEO, Yehiel Tal. "CollPlant's breast implants in development are unique in that they are designed to regenerate breast tissue as well as have inherent safety advantages. This would be paradigm-shifting in a market that has maintained such a large demand yet has seen increasing issues with safety over the last few decades. A primary goal of this study is to obtain data which would then support the optimization of the implant design and apply this design to a pivotal large-animal study that is intended to be the subject of discussions with the FDA."
|
XRTX | Hot Stocks07:04 EST Xortx Therapeutics appoints Patrick Treanor to board of directors - XORTX Therapeutics welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023. Treanor is the current Chief Operating Officer of Pathalys Pharma, Inc., a private company focused on the development of advanced therapeutics to improve the management of late stage chronic kidney disease. In connection with the appointment of Patrick Treanor, XORTX has granted, in accordance with the Company's stock option plan, 8,000 options to purchase common shares of the Company at an exercise price of $2.90 for a period of five years.
|
BMY | Hot Stocks07:03 EST Bristol Myers' repotrectinib application validated by EMA - Bristol Myers announced that the European Medicines Agency - EMA - has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor - TKI - repotrectinib as a treatment for ROS1 TKI-naive and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, or NSCLC, and TKI-naive and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced or metastatic solid tumors. The application was based on results from the registrational Phase 1/2 TRIDENT-1 trial and CARE study. Validation of the application confirms the submission is complete and begins the EMA's centralized review procedure. In the TRIDENT-1 and CARE trials, repotrectinib demonstrated clinically meaningful response rates in patients across ROS1-positive NSCLC and NTRK-positive solid tumor cohorts. Durability of response was robust and intracranial responses were observed in both settings, as well as in patients whose tumors harbor common resistance mutations. The safety profile of repotrectinib was well characterized and generally manageable with routine standard-of-care treatments. In November 2023 the FDA approved Augtyro - repotrectinib - for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. Turning Point Therapeutics is a wholly owned subsidiary of the Bristol-Myers Squibb Company. As of August 2022, Bristol Myers Squibb acquired the company, including its asset repotrectinib.
|
BITF | Hot Stocks07:03 EST Bitfarms produces 446 bitcoin in December - Bitfarms provides an update for the month and year ended December 31, 2023. December production of 446 BTC represented an increase of 13.8% from November as high uptime and a surge in transaction fees of 465% offset a network difficulty increase of 6.0% during the month. For the year ended December 31st, network difficulty increased 103.6% while the BTC price was up approximately 156.8%, resulting in a 61.4% improvement in YOY production economics as measured by USD/TH/day. "In 2023, we executed our growth plan and laid the groundwork for aggressive growth in 2024. We finished the year with $118 million in liquidity, low-cost power contracts for up to 593 MW and a miner purchase agreement for up to 63,888 new Bitmain miners in 2024," said Geoff Morphy, CEO of Bitfarms. "Nearly 70% of new miners will be deployed in our existing US and Canadian farms with the remaining miners earmarked for the Paso Pe, Paraguay expansion, which is currently running ahead of schedule. We are well underway to achieve our Q2 2024 goals of 12 EH/s and 310 MW operating capacity, which would represent increases of 85% and 29%, respectively, compared to year-end 2023. Additionally, we maintain optionality under the contract with the potential to achieve 17 EH/s and 23 w/TH fleet efficiency before the end of 2024.
|
FEAM | Hot Stocks07:02 EST 5E Advanced Metals commences mining operations at 5E Boron Americas Complex - 5E Advanced Materials has officially begun mining operations at the Company's 5E Boron Americas Complex with the startup of the wellfield injection process. The Company is now working under its EPA UIC permit to begin extracting valuable minerals from its wholly owned project at Fort Cady. The Company recently announced its operational plan and has now started wellfield operations with the goal of completing outstanding operational items at the facility in parallel. 5E expects to begin lab production in the short-term and production of boric acid and lithium carbonate from the small-scale facility by the end of the first calendar quarter of 2024. This initial production will be used for customer qualification as the Company seeks to obtain bankable offtake agreements and future sales to support FEL 2 engineering as the Company focuses on commercial scale.
|
SATS DISH | Hot Stocks07:02 EST EchoStar completes merger with Dish - EchoStar (SATS) announced the completion of its acquisition of DISH Network (DISH) on December 31, 2023. To complete the acquisition, a wholly owned subsidiary of EchoStar merged with and into DISH Network, with DISH Network surviving the merger as a wholly owned subsidiary of EchoStar. As previously announced, as a result of the merger, each share of DISH Network Class A Common Stock and DISH Network Class C Common Stock converted into 0.350877 shares of EchoStar Class A Common Stock, and each share of DISH Network Class B Common Stock converted into 0.350877 shares of EchoStar Class B Common Stock.
|
VYGR NVS | Hot Stocks07:02 EST Voyager Therapeutics enters capsid license agreement, collab with Novartis - Voyager Therapeutics (VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NVS) to advance potential gene therapies for Huntington's disease, HD, and spinal muscular atrophy, SMA. Voyager will provide Novartis a target-exclusive license to access Voyager's TRACER capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD. Under the terms of the agreement, Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager's TRACER capsids. Novartis will obtain target-exclusive access to Voyager's TRACER capsids related to SMA for the duration of the agreement and will be responsible for all development and commercialization. Novartis will also receive worldwide rights to Voyager's AAV gene therapy for HD, leveraging Voyager's TRACER capsids and proprietary payloads.
|
LLAP | Hot Stocks06:51 EST Terran Orbital sees year-end cash balance in excess of $70M - Terran Orbital pre-announced its 2023 year-end cash balance. Terran Orbital expects to report an excess of $70M in cash and cash equivalents as of December 31, 2023, compared to cash and cash equivalents of $38.7M as of September 30, 2023, primarily resulting from the receipt of key customer payments at year-end. "We are entering 2024 with a strong financial foundation that we believe will enable us to continue to execute on our strategic and operational objectives," said Marc Bell, Terran Orbital's Co-Founder, Chairman, and CEO.
|
NRXP | Hot Stocks06:49 EST NRx Pharmaceuticals announces plan to regain compliance with Nasdaq - NRx Pharmaceuticals announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed Securities, or MVLS. As has been previously disclosed, Nasdaq presented NRx with two deficiency notices, one related to failure to maintain the minimum $1 bid price and the other related to failure to maintain the minimum MVLS for the Nasdaq Global Market. Because there were two simultaneous deficiencies, the company did not qualify for a second automatic 180-day compliance period on the bid price deficiency.
|
NI BX | Hot Stocks06:35 EST NiSource completes NIPSCO minority equity interest transaction - NiSource (NI) completed the issuance of a 19.9% indirect equity interest in the company's Northern Indiana Public Service Company - NIPSCO - subsidiary to an affiliate of Blackstone Infrastructure Partners ("Blackstone Infrastructure"), the dedicated infrastructure group of Blackstone (BX). Through the transaction the Blackstone affiliate has acquired a 19.9% non-controlling equity interest in NIPSCO Holdings II, which owns all the equity interests of NIPSCO, and NiSource will own the remaining 80.1% of NIPSCO Holdings II. Blackstone Infrastructure is committed to investing behind NIPSCO's energy transition and decarbonization programs. NiSource intends to use the capital infusion to support its utility, strengthen its balance sheet and fund ongoing capital needs associated with the renewable generation transition underway. NIPSCO is Indiana's largest vertically integrated electric and gas distribution company, providing utility service to almost 1.3 million customers.
|
FREY | Hot Stocks06:32 EST Freyr Battery completes redomicile from Luxembourg to the U.S. - Freyr Battery completed its previously announced process to redomicile from Luxembourg to the United States effective December 31, 2023. In connection with the completion of the redomiciliation, each of the issued and outstanding of the company's previous Ordinary Shares and public and private Warrants have become, on a one-for-one basis, shares of Common Stock and Warrants, respectively, of Freyr Battery, Inc., a Delaware corporation. The company expects that trading of the Freyr Common Stock and Warrants will commence under the same symbols on the New York Stock Exchange as of the open of business this morning, January 2, 2024.
|
LLAP | Hot Stocks06:32 EST Terran Orbital receives payment from Rivada - Terran Orbital received a payment from Rivada Space Networks pursuant to the company's previously announced contract with Rivada. The amount was for the completion of a program milestone. As a result, Rivada is current on all outstanding invoices. The company expects to receive additional milestone payments in 2024 and continues to expect to meet its delivery obligations under the Rivada Contract on schedule in 2025 and 2026. The company does not plan to provide any further updates or otherwise publicly comment on the Rivada contract.
|
MNKD | Hot Stocks06:07 EST MannKind and Sagard Healthcare sign royalty purchase agreement for up to $200M - MannKind sold a 1% royalty in net sales of Tyvaso DPI inhalation powder in exchange for up to $200M, including the purchase price of $150M and an additional potential milestone payment of up to $50M. United Therapeutics licensed Tyvaso DPI from MannKind in 2018 and began marketing it in June 2022 for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following FDA approval. Pursuant to a license agreement with United Therapeutics, MannKind is entitled to a 10% royalty on net sales of Tyvaso DPI, subject to certain reductions. Under the terms of the royalty purchase agreement, Sagard Healthcare will receive royalty payments equal to 1% of the net sales of Tyvaso DPI that occur between October 1, 2023 and December 31, 2042, with MannKind retaining a 9% royalty.
|
IBRX | Hot Stocks06:04 EST ImmunityBio announces up to $320M in investment from Oberland Capital - ImmunityBio announced an up to $320M royalty financing and equity investment in the company by Oberland Capital, with $210M of gross proceeds received at closing on December 29, 2023. The additional capital provides financial resources for the company to accelerate its commercialization efforts in anticipation of a potential regulatory approval, as well as to expand its pipeline within the broader urological cancer space. The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 - Anktiva - indications into multiple solid tumors. ImmunityBio's commercialization efforts are in anticipation of potential FDA approval of Anktiva in combination with Bacillus Calmette-Guerin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer - NMIBC - with carcinoma in situ - CIS - with or without Ta or T1 disease. The company resubmitted its Biologics License Application to the FDA, and the FDA set a user fee goal date for the BLA resubmission of April 23, 2024. The investment from Oberland Capital takes the form of a $300M Revenue Interest Purchase Agreement that is non-dilutive to current investors, of which $200M was funded at closing, and $100M is to be funded contingent upon FDA approval of the company's BLA for Anktiva. Oberland Capital will have a right to receive initially tiered single-digit royalty payments on net sales of the company's products, which are capped at a multiple of their investment. In addition, the company has entered into a purchase agreement with Oberland Capital for the private placement of 2,432,894 shares issued at closing, representing $10M of gross proceeds based on the trailing 30-trading days VWAP. Oberland Capital has also an option to purchase an additional $10M of common stock at a future date.
|
ENSG | Hot Stocks06:02 EST Ensign Group acquires skilled nursing facilities in Tennessee, Nevada - The Ensign Group announced that it acquired the operations of TriState Health and Rehabilitation Center, a 116-bed skilled nursing facility located in Harrogate, Tennessee. This acquisition was effective January 1, 2024 and is subject to a long-term, triple net lease. In a separate transaction on the same day, Ensign announced that its affiliate acquired the operations of Hearthstone Health and Rehabilitation, a 125-bed skilled nursing facility located in Sparks, Nevada.
|
AGR PNM | Hot Stocks05:28 EST Avangrid issues statement on termination of PNM Resources merger - Avangrid (AGR) issued the following statement on the previously announced merger agreement with PNM Resources (PNM). "Since 2020, Avangrid, a national leader in clean energy, has fought to gain approval of its merger with PNM, a merger that would bring over $300 million in benefits to PNM consumers and communities and utilize the company's vast experience, and the experience of Iberdrola, S.A., a global leader at the forefront of the energy transition, to help the state achieve its clean energy goals. Avangrid and PNM had obtained all the necessary regulatory approvals for the closing of the merger by the end of 2022 except the approval of the New Mexico Public Regulation Commission. However, with the close of 2023 there is still no clear timing on the resolution of the court review of the New Mexico regulator's denial of the merger nor any subsequent regulatory actions. Avangrid has terminated the merger agreement because all final regulatory approvals were not received by December 31, 2023, the end date under the merger agreement after which either Avangrid or PNM could terminate the merger agreement if the merger had not yet been consummated. In connection with the termination of the merger agreement, the commitment letter, pursuant to which Iberdrola agreed to provide or arrange for funds to the extent necessary for Avangrid to consummate the merger, terminated automatically by its terms. Avangrid intends to continue to focus on its robust growth opportunities, with over $9 billion in incremental capital projects organically secured during the pendency of the merger. We will focus on delivering over $5 billion in capital projects under our New York and Maine multi-year rate plans plus an incremental $2 billion in capital projects related to clean energy transmission in New York (CLCPA II), repowering over $5 billion of renewable assets under the benefits of the Inflation Reduction Act, and developing new renewable energy projects, including powering Vineyard Wind, the first large scale offshore wind project in the nation, which will further cement Avangrid as a national leader in clean energy. While our merger agreement with PNM has been terminated, we remain more than ever steadfast in our commitment to New Mexico in the development of wind and solar renewables, helping explore options in the new hydrogen economy, and delivering on the partnership with the Navajo Nation to achieve its clean energy future. Also, with no major transaction consummated in 2023, we reaffirm our EPS and Adjusted EPS 2023 guidance as presented without the impact of Renewables transactions that we had previously provided during our third quarter earnings presentation on October 26, 2023. Avangrid will continue its national and global legacy of climate stewardship by working tirelessly to bring clean, affordable, and renewable energy to New Mexico and the 23 states we operate in across the nation."
|
GLPG | Hot Stocks05:26 EST Galapagos signs agreement to transfer Jyseleca business to Alfasigma - Galapagos and Alfasigma announced that they have signed an agreement to transfer Galapagos' Jyseleca business to Alfasigma. The agreement follows the signing of a letter of intent as announced on October 30, 2023. Subject to, and as part of the closing of the transaction, Michele Manto, Galapagos' chief commercial officer, will join Alfasigma, and has resigned from his position as chief commercial officer and executive committee member at Galapagos at the end of December 2023. Subject to, and as part of the closing of the transaction, Michele Manto, Galapagos' chief commercial officer, will join Alfasigma, and has resigned from his position as chief commercial officer and executive committee member at Galapagos at the end of December 2023. In connection with the transaction, Galapagos expects to realize substantial savings ranging between EUR 150M and EUR 200M and will prioritize investments in its existing technology platforms of small molecules, CAR-T cell therapies and biologics, as well as the scale-up of its innovative decentralized CAR-T manufacturing network. In addition, Galapagos plans to invest in licensing and acquisition opportunities ranging from late preclinical to mid-stage clinical assets in its strategic therapeutic areas to drive value across its pipeline. As previously announced, under the terms of the agreement, Alfasigma will acquire the entire Jyseleca business, including the European and UK marketing authorizations, the commercial, medical affairs and development activities for Jyseleca and approximately 400 Galapagos positions in 14 European countries. Galapagos will receive a EUR 50M upfront payment, potential sales-based milestone payments totaling EUR 120M and mid-single to mid-double-digit royalties on European sales. Galapagos will contribute up to EUR 40M to Alfasigma by June 2025 for Jyseleca related development activities.
|
WKEY | Hot Stocks05:22 EST WISeKey secures investment from THA to expand Hedera network, cryptocurrencies - WISeKey, through its subsidiary WISe.ART announced the closing of a strategic investment round with The Hashgraph Association, or THA, a Swiss-based non-profit association that is accelerating broad adoption of the Hedera network globally. The company said this milestone investment is set to propel the expansion and utilization of the Hedera network and further the development of the innovative WISe.Art and SEALCOIN cryptocurrencies. Hedera offers ultra-low transaction fees, blazing-fast network speeds, high scalability, and real-time settlement to empower the next-generation of digital finance. .
|
PNM AGR | Hot Stocks05:19 EST PNM Resources announces termination of merger agreement with Avangrid - PNM Resources (PNM) announces the termination of its merger agreement with Avangrid (AGR). While the PNM Resources board of directors approved an extension, it was not accepted by Avangrid and Avangrid terminated the merger. The companies' merger agreement, announced in October 2020, had been extended through December 31, 2023, while awaiting a decision from the New Mexico Supreme Court on the January 2022 appeal of the New Mexico Public Regulation Commission decision denying the transaction. All other federal and state approvals had been received in 2021.
|
MXCT | Hot Stocks05:16 EST MaxCyte appoints Maher Masoud as CEO - MaxCyte confirmed the appointment of Maher Masoud as president and CEO of MaxCyte effective as of January 1. In addition, Masoud now serves as a director on MaxCyte's board of directors.
|
GOGL | Hot Stocks05:15 EST Golden Ocean appoints Lars-Christian Svensen CEO - The board of Golden Ocean announced the appointment of Lars-Christian Svensen as the CEO of Golden Ocean with effect from January 1. Svensen currently serves as the interim CEO of Golden Ocean Management AS. Prior to that, he held the role as Golden Ocean's chief commercial officer.
|
CNHI | Hot Stocks05:10 EST CNH Industrial delists from Euronext Milan - CNH Industrial announced that it has completed the voluntary delisting of its shares from Euronext Milan. Shares of CNH are now solely listed on the New York Stock Exchange.
|
CNHI | Hot Stocks05:10 EST CNH Industrial delists from Euronext Milan - CNH Industrial N.V. (NYSE: CNHI) announces that it has completed the voluntary delisting of its shares from Euronext Milan. Shares of CNH are now solely listed on the New York Stock Exchange.
|